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Pathology laboratories throughout the world have compiled large archives 
of unique collections of tissue specimens. These tissue samples are used for 
patient diagnostics and research. Novel molecular insights into alterations in 
normal cellular function have led to the identification of targets for innovative 
therapies. Testing for biomarkers combined with molecular pathology has created 
the potential for “personalized medicine” and improved diagnosis, treatment 
and prognosis. New technologies for molecular analysis in molecular tumor 
diagnostics and research must be developed and implemented to keep pace 
with the latest insights, resulting in a constant cycle of change. Such translational 
research can only progress if patient material can be accessed from the archives 
for further study. The resulting new insights and strategies will eventually be 
implemented in patient care. 
This thesis describes three important issues in this cycle of change with a focus 
on molecular pathology. 
First, due to advances in the treatment of cancer, the amount of patient material 
that is available for diagnostics and research is decreasing, while the number of 
requests for diagnostics is rapidly increasing. Early diagnosis and the increasing 
application of neoadjuvant therapies are primarily responsible for this trend. The 
latter is, without a doubt, beneficial to the patient but makes the (molecular) 
diagnostics of the material increasingly challenging. 
Before molecular techniques can be applied for diagnostics or research, 
nucleic acids must be extracted from the archived tissue. Because the tissue 
is fixed in formalin and embedded in paraffin, the nucleic acids are crosslinked 
and fragmented and, consequently, of poor quality. Therefore, DNA isolation 
procedures must be improved, and if the amount of DNA remains too low for 
biomarker testing, analysis methods such as whole genome amplification should 
be considered.
Second, new state-of-the-art technologies must be developed constantly. 
Methods should be validated and implemented and be applicable for use with 
the small amounts of DNA isolated from tissue that is heavily degraded in the 
embedding process. 
The third focus of this thesis is the use of bio-informatics approaches. For the 
genomic data analysis of tumors in some applications, only limited analysis 
software is available. In a research environment, new tools must be developed, 
applied, or adapted for the analysis of the acquired data. After validation, these 
tools can be implemented in the daily routine of molecular tumor diagnostics. 
In chapter 1, developments in pathology over the centuries and molecular 
technology and pathology in recent decades are summarized in a historical 
perspective. Some important genes and interesting genomic phenomena are 
highlighted in the context of their clinical implications. Guided by the description 
of a DNA analysis pipeline, the three different foci of this thesis, pre-analysis 
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technologies, technological advances and analysis strategies, are further 
introduced. Chapter 2 demonstrates how DNA can be isolated from formalin-
fixed, paraffin-embedded (FFPE) material and compares two different techniques: 
a manual method and a fully automated DNA isolation method. Chapters 3 
and 4 describe multiplex ligation-dependent probe amplification (MLPA) as an 
assay for the detection of multiple chromosomal deletions in tumor tissue in a 
single experiment. We developed and validated a MLPA-based assay to identify 
chromosomal losses in formalin-fixed and paraffin-embedded oligodendroglial 
tumors. To assure a reliable workflow for this technology, a data management 
system, MLPAInter, was developed to interpret the MLPA data stream. Chapter 
5 reveals how limited amounts of DNA can be amplified in a whole-genome 
amplification (WGA) process in which a two-step mutation screening protocol is 
applied. First, a high-resolution melting analysis (HRM) is used as a prescreening 
method for samples harboring mutations, and direct Sanger sequencing is then 
employed for the final diagnosis of the mutations. The KRAS gene was used as 
a model system because the accurate detection of KRAS mutations is critical 
for the molecular diagnosis of cancer and may guide proper treatment selection. 
In chapter 6, the reliability with which allele-specific quantitative real-time PCR 
with hydrolysis probes could be performed on fine-needle aspirates from non-
small-cell lung cancer (NSCLC) patients was studied by comparing the results 
with histological material from the same patients. Finally, future directions and 
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Pathology: a historical perspective
The history of pathology began 3500 years ago with the documentation of disease 
by the Egyptians. Throughout the centuries, individuals in the Greek (Hippocrates 
and Aristotle, 4th century BC), Roman (Celsus, 1st century AD, and Galen, 2nd 
century AD), medieval Byzantine (Aetius, 6th century AD) and Arab (Avicenna 
and Avenzovar, 11th century AD) empires contributed to the medical field. [1] It 
can be claimed that anatomical pathology, or pathology as a separate medical 
specialty, began with the work of the Florentine physician Antonio Benivieni (1443-
1502) [1,2]. Benivieni described autopsies and case histories and his work was 
published titled De Abditis Morborum Causis (The Hidden Causes of Disease). 
Some of his autopsy protocols are similar to those currently in use [2]. The first 
modern book of anatomy is mostly attributed to Andreas Vesalius (1514-1564). 
He published his De humani corporis fabrica (The Fabric of the Human Body) in 
1543 (Nutton 2012). In 1554 Jean Francois Fernel (1497-1558) introduced the 
term “Pathology” in his Medicina [3]. 
The work of these pioneers was continued by others, including Giovanni Batista 
Morgagni (1682-1771) who started correlating signs and symptoms with findings 
at dissection, John Hunter (1728-1793) considered founder of scientific surgery, 
Mathew Baillie (1761-1823) by introducing the systematic study of pathology 
and Marie Francois Xavier Bichat (1771-1802), who contributed to the founding 
of histology [1,4–7]. Unfortunately, all this work did not contribute much to the 
health of the individual patient. Many pathological observations were made post-
mortem, and patient treatment did not significantly improve for centuries [8]. 
Pathology was inseparable from other medical specialties, and individuals often 
had both pathological and clinical skills [1].
New spectacular developments in pathology arose in the mid-nineteenth 
century, largely because of the introduction and implementation of novel medical 
technologies; for the first time, it became common practice to apply pathological 
findings in patient care. Together with these changes, pathology developed as an 
independent medical profession. Thomas Hodgkin (1798-1866), later known for 
the eponymous disease, was one of the first to recognize that the “microscope 
might lead to useful discoveries in the future” [1]. Indeed, the microscope 
changed pathology by making it possible to histologically examine tissue on the 
cellular level. Since Rudolf Virchow published his text entitled Cellular Pathology 
in 1858, the basic understanding of cancer has greatly changed from an organ-
based disease to a cell-based disease [9,10]. During this time period, along with 
anatomical pathology, “surgical pathology” was introduced in 1819 [10]. Other 
technological advances further enhanced the ability to pathologically examine 
tissue. In 1863, the introduction of the natural dye hematoxylin, derived from 
the logwood tree (Haematoxylum campechianum), led to the first successful 
description of the hematoxylin staining technique that is utilized today [11]. 
Beginning in 1826 synthetic aniline dyes were developed and contributed to 
the development of numerous histochemical stains [12]. The introduction of 
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the freezing microtome in the 1870s, paraffin wax embedding (1869, Edward 
Klebs) and tissue fixation with formaldehyde (1893, Ferdinand Blum) began 
a new area for the “modern” pathologist. It became possible to pre- or intra-
operatively contribute to the diagnosis and treatment of a patient [10]. In the 
1870s, Carl Ruge, a German gynecologist, microscopically diagnosed cervical 
and uterine cancer and may have been one of the first international consultants 
to interpret material from other countries [13]. In the 1890s, frozen sections were 
examined during breast cancer surgery. In this early period of surgical pathology, 
misdiagnosis and technological issues contributed to debate on the usefulness 
of these technologies, which lasted until additional technological advances were 
introduced in the pre-World War II era [10]. In 1941, Albert Coons and colleagues 
labeled an antibody with a fluorescent dye and used it to identify an antigen in 
tissue sections: Immunohistochemistry (IHC) was born. Since that time, tumor 
diagnosis has relied primarily on histopathological and immunohistological 
features [14,15]. 
The dawn of another era that significantly influenced pathology was at the 
horizon, “Molecular Pathology”. Although the cellular nature of tumors was 
described in the early nineteenth century, it was not until 1890 that David Paul 
von Hansemann (1858-1920), a German pathologist and a coworker of Rudolf 
Virchow, introduced the term “anaplasia” and proposed that normal cells are 
converted to tumor cells when they acquire chromosomal abnormalities[16]. 
At the same time, Theodor Boveri (1862-1915), who did not focus his studies 
on cancer, applied his observations of dividing sea urchin eggs and their 
abnormalities to what he perceived to be the genetic basis of malignancy. In 
1914, he formulated 20 specific hypotheses regarding cancer biology in his book 
zur Frage der Entstehung maligner Tumoren; almost all of these hypotheses 
have been verified by studying cancer chromosomes in the 100 years after his 
publication [16,17]. These discoveries would not have been possible without yet 
another breakthrough that revolutionized pathology. 
This was the description of the DNA double helix in 1953 by Watson and Crick [18]. 
This was the starting point of many new developments in molecular technologies 
which yielded many new insights into the molecular pathogenesis of cancer. 
These insights have had a large impact on cancer diagnosis, prognosis and 
therapeutics [19]. Fluorescence in situ hybridization (FISH) was first described 
in 1969 [20] and was applied in clinical diagnostics to detect HER2 amplification 
in breast cancer in 1992 [21]. The application of Southern blotting [22] and 
comparable techniques, such as pulsed-field gel electrophoresis [23], allowed 
researchers to identify molecular variations more rapidly. The construction of 
molecular probe collections and the discovery of restriction fragment length 
polymorphisms (RFLPs) enabled the mapping of the human genome [24] and 
the positioning of many genes [25–27] (figure 1). The study of the molecular 
basis of disease was further facilitated by the development of the polymerase 
chain reaction in the early 1980s at Cetus Corporation in California. Kary Mullis 
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was awarded the Nobel Prize for chemistry in 1993 for his contributions [28]. The 
introduction of fluorescent PCR, in which the increase in fluorescence per cycle 
can be monitored, made PCR the method of choice for gene expression studies 
and direct mutation analysis (Deepak et al., 2007). 
Sanger sequencing was described in 1977 [29], and the combination of this 
method with PCR led to the detection of point mutations, polymorphisms and 
other small DNA rearrangements [30]. Sanger sequencing was most likely the 
first molecular methodology suitable for high-throughput, fully automated data 
acquisition and commercialization [31] and led to the first complete sequencing of 
the human genome [32,33]. With the introduction of massive parallel sequencing 
or “next-generation” sequencing strategies, DNA sequencing costs were 
dramatically reduced. The 1000 Genomes Project was consequently launched in 
2008 [34–36], and reliable sequencing and analysis of complete cancer genomes 
became possible [37].
Figure 1. An additional MspI RFLP at the 
human hepatic lipase (HL) gene locus.
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These technological advances over the years have and will continue to have 
a large impact on cancer research. Molecular pathology in combination with 
molecular tumor diagnostics has become standard hospital practice for genetic 
and genomic testing for clinically relevant discoveries in cancer [38,39]. 
The discovery of activating mutations in BRAF in several cancer sub-types in 
2002 and the report of activating mutations in EGFR in lung cancer [19] in 2004 
led to the development of high-throughput molecular screening methodologies. 
Personalized medicine has become an important strategy for oncologists, with 
the consequent need to test small or limited amounts of material and deliver 
the test results to the clinic as quickly as possible [40,41]. This all contributed 
to unprecedented beneficial outcomes for oncology patients. One of the most 
imaginative examples is the “Lazarus” effect, the concept that patients almost 
literally rise from the dead, on lung cancer patients with a specific EGFR mutation, 
and therefore a poor prognosis, that are subsequently treated with tyrosine kinase 
inhibitors [42]. 
Pathology: a local perspective
Leiden University, founded in 1575, and the Leiden University Hospital have a 
long history of developing and implementing novel ideas and technologies in 
anatomical and clinical pathology. In 1593, one of the first anatomical theaters 
in Europe was established [43]. A reconstruction of this theater can be visited in 
the Boerhaave museum in Leiden. Nicolaes Tulp (1593-1674), later portrayed 
by Rembrandt in “The Anatomy Lesson of Dr Nicolaes Tulp”, studied medicine 
in Leiden and, after moving to Amsterdam, contributed to medicine with his work 
Observationes Medicae. In it, he described in detail more than 200 cases of 
disease and death [44]. 
In the same period, Franciscus de le Boë Sylvius (1614-1672) came to Leiden 
as a physician and anatomist. At his instigation, the first University Chemical 
laboratory in Europe was founded in 1669 [45]. One of his students was 
Theodor Kerckring (1638-1693), who published the Spicilegium anatomicum, an 
anatomical atlas of clinical observations, medical curiosities, autopsy discoveries 
and general anatomical information. He used a microscope to investigate the 
folds in the small intestine [46]. 
Herman Boerhaave (1668-1738) made an important contribution to pathology by 
publishing autopsy reports of patients with a documented recent medical history 
[1]. Bernhard Siegfried Albinus (1697-1770), one of Boerhaave’s students, 
became one of the most famous anatomy teachers in Europe. In his work, Tabulae 
sceleti et musculorum corporis human, Albinus and his coworker, the artist and 
engraver Jan Wandelaar (1690-1759), employed a novel technique to increase 
the scientific accuracy of the anatomical illustrations. It was based on the artists’ 
traditional drawing-frame, which contained a grid to achieve systematic control 
over the rendering from a precisely established viewpoint [47]. 
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Figure 2. Leiden Professors of 
Pathology in the 19th and 20th 
century. 
A
S.S. Rosenstein (1832-1906) 
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Gerard Conrad Bernard Suringar (1802-1874) contributed to this early part of the 
“Leiden history of medicine” by publishing 18 articles on it in the Nederlandsch 
Tijdschrift voor Geneeskunde between 1860 and 1870. Allard Calcoen, in his 
thesis Onder Studenten [48] describes the role of Leiden pathologists contributing 
to new directions in pathology in the second half of the 19th century. 
Samuel Siegmund Rosenstein (1832-1906, figure 2), a prominent student of 
Rudolf Virchow became, after a period in Groningen, a professor at Leiden 
in 1873. He was one of the first clinicians in the Netherlands to recognize the 
importance of micro-organisms as a cause of infectious disease, and he was the 
first to describe and demonstrate the presence of tuberculosis cells in patients with 
kidney tuberculosis [48]. In 1899, he reminisced about the significant progress in 
the clinical treatment of patients, especially in the second half of the 19th century. 
Medicine moved from a time when theoretical and practical medicine were distinct 
to a period of close collaboration between physiological and pathological anatomy 
and the clinic, which he described as a “threefold alliance”. As examples of the 
technical advances that contributed to this alliance, he described the application 
of the ophthalmoscope, the laryngeal mirror and the thermometer and laboratory 
developments in electric equipment, microscopy, the microtome and staining 
methods. Significant breakthroughs in surgery, bacteriology and pharmacology 
also contributed to improved patient care [49].
Other pioneers in this “new directions in medicine” included Theodorus Henricus 
MacGillavry (1835-1921, figure 2) and Daniel Eliza Siegenbeek van Heukelom 
(1850-1900, figure 2). Macgillavry, once characterized as “a man who can think 
microscopic”, employed light microscopy techniques to study human leukemia 
[50]. When he arrived at Leiden, he remarked that the University was flourishing; 
however, he was unable to find a space that, in his opinion, could rightly be 
named a “Pathological Laboratory” unless “pathologically would be translated 
as inadequate and laboratory by booth.” He sometimes performed pathological 
experiments in his house. His efforts contributed to the construction of a new 
laboratory that opened in 1885: The Boerhaave Pathologic Anatomic Laboratory 
located at Steenstraat 1A in Leiden (Figure 3). Siegenbeek van Heukelom, another 
skilled microscopist, garnered the most fame in the area of medicina forensis. 
In his capacity as ‘police doctor’, he observed organic changes in individuals 
who died post-operatively or collapsed after receiving chloroform anesthesia and 
consequentially contributed to the reduced use of chloroform as an anesthetic 
[48]. 
Nicolaas Philip Tendeloo (1864-1945) elevated the level of study in general 
pathology and pathological anatomy in the Netherlands, and a new laboratory for 
general pathology, anatomy and forensic medicine was designed and built based 
on his ideas and opened in 1925 at Wassenaarseweg 62/70 (Figure 3) [51,52]. 
This laboratory was used until 1994, when the department of pathology moved 





Upper: The Boerhaave Pathologic Anatomic Laboratory at Steenstraat 1A, Leiden. In use 
from 1885-1925. Photo by amanuensis A. Mulder 1915. 
Lower: Pathology Laboratory at Wassenaarseweg 62, Leiden. In use from 1925-1994. 
Photo by K.G. van der Ham, ca. 1993.
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“Quo vadis?” was the intriguing title of an article published in 1952 in the 
“Nederlandse tijdschrift voor Geneeskunde” by George Otto Emile Lignac (1891-
1954, figure 2) [53]. After reviewing the history of pathology, he predicted the 
biological importance of ribonucleotides and deoxyribonucleotides and concluded 
by stating: “Van de cellulaire tot de moleculairer pathologie, zal men zeggen. 
Inderdaad, deze weg moet onvermijdelijk worden begaan”, which means:
“From cellular to molecular pathology, man will say: Indeed, this road must 
inevitably be chosen”. And indeed, that road was taken.
An early reference to the use of molecular technology in the department is found 
in the 1958-1959 Pathology Annual Report. It states that Aart Schaberg (1918-
1999, figure 2) initiated research to image chromosomes in malignant tumors 
(Verslag over de cursus 1958-1959, p4-§G3
As early as 1954, the year that Prof. Lignac tragically died in an airplane crash, 
Piet van Duijn (1921-2007) published a “new method” for the “combined staining 
of DNA and a number of polysaccharides” [54]. Theo van Rijssel (1917-1994, 
figure 2) succeeded Lignac in 1956, and he united diagnostics, educational and 
research. Several new technologies were introduced [55]. In the early 1960s 
Piet van Duijn expanded his interest to quantitative cytochemistry of DNA in the 
nucleus of different cell types and at different stages of cell division. He and his 
coworkers contributed much to the automation of cytochemical and cytogenetic 
analysis and the introduction of FISH (fluorescent in situ hybridization) in 
cytogenetic diagnosis. (van Duyn, 1960) (http://www.knaw.nl, accessed January, 
2013). 
In the same period and in collaboration with the Department of Histo and 
Cytochemistry, Sebastiaan Ploem developed an epi-illuminator known as the 
Ploem-opak, which has become an indispensable element in fluorescence 
microscopy (Cicero 2005, vol 12, p9). 
The creation in 1971 of the “Foundation Pathological Anatomical National 
Automated Archive” (PALGA) was important for pathology in the Netherlands. 
Philippus Jacobus Hoedemaeker (1937-2007, figure 2) was one of the founders. 
Because of this system, the national cervical cancer screening study successfully 
began. Since then, the PALGA database has become a valuable resource for PA 
departments in the Netherlands to quickly and efficiently diagnose and determine 
the best treatment for cancer (http://www.knaw.nl, accessed January, 2013). 
In the 1970s and 1980s, Cees Cornelisse, Dirk Ruiter, Philip Kluin and Gert-Jan 
Fleuren (head of the department 1993-2012), supported by their coworkers, further 
developed the molecular research in the department. DNA imaging technology 
and flow cytometry were used for the analysis of cervical and ovarian cancer 
[56–58]. From the early 1990s, in situ hybridization and chromosome and cosmic 
libraries were made available and used for the interpretation of chromosomal 
rearrangements [59–62]. PCR was introduced [63] and used to detect the loss 
of heterozygosity in fresh and archival tissue [64,65]. Polymorphic microsatellite 
markers were used to type flow cytometric sorted cells [66,67] and to identify 
potentially mixed-up samples [67]. 
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Because of its clinical relevance, molecular diagnostic testing was first used in 
1992 when clonality testing was performed using Southern blotting on 32 T-cell 
lymphomas (Jaarverslag Laboratorium voor Pathologie 1992, p28§F). Under 
the supervision of Hans Morreau, a preliminary list for molecular pathological 
indications was prepared in 1997, and in 1998 a quality control system for 
molecular testing was implemented in the laboratory (Jaarverslag Laboratorium 
voor Pathologie 1997, p32§E). In 1996, the first automated DNA sequencer, a 
gel-based ABI Prism® 377, was implemented in the laboratory, enabling new 
molecular testing techniques that focused on loss of heterozygosity (LOH) 
detection and microsatellite instability testing in colorectal cancer.
Since 1992, the number of molecular diagnostic consultations has increased to 
over 3000 in 2010. Over the years, there has been a constant demand for the 
development, validation and implementation of new and often high-throughput 
molecular technologies. In addition, new technological developments have been 
applied in the laboratory for molecular research. In 2003, the tissue microarray 
technique, which was developed by Sauter and Kallionemi [68], was introduced 
in Leiden [69], followed by microarray-based gene expression technologies 
[70]. Microarrays based on single nucleotide polymorphisms (SNPs) were 
used to detect the genome-wide loss of heterozygosity and other chromosomal 
aberrations [71,72], and since 2009, the first steps toward high-throughput 
sequencing have been made.
Pathological workflow
Tumor tissue becomes available for pathological examination at various disease 
stages through pre-operative testing by fine needle aspiration, tissue biopsy 
and the surgical treatment of patients with cancer. After delivering the crude 
material to the Department of Pathology, representative tissue samples are taken 
for further processing, including formalin-fixation and paraffin-embedding. In 
Dutch academic centers such as the LUMC, pathology departments maintain a 
systematic archive with millions of FFPE tissue blocks that have been collected 
and stored over the years. The oldest series of accessible paraffin blocks in the 
LUMC Department of Pathology dates back to 1946, and we estimate that a total 
of over 2.2 million blocks have been archived over the last 65 years.
To examine the material, pathological tissue sections are cut from the FFPE 
blocks with a microtome, stained with hematoxylin and eosin and delivered to the 
pathologist for initial examination and diagnosis. 
The pathologist can further refine his diagnosis by making use of a selection of 
immunostaining, microscopy and molecular analysis techniques. After a molecular 
request is made, nucleic acids are extracted, the requested molecular analysis 
is performed and the results are reported and integrated in the pathological 
reports, which are communicated to the clinic. The remaining material is stored 
in the archives. Patient material can be subsequently used for scientific research 
and analysis according to medical ethical guidelines described in the Code for 
Proper Secondary Use of Human Tissue established by the Dutch Federation 
of Medical Sciences (http://www.federa.org, accessed January, 2013) as well as 
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local medical ethical guidelines. According to these guidelines, all human material 
used in research studies should be anonymized.
All clinical pathology processes are defined in protocols and standard operating 
procedures. The process of molecular analysis can be defined in a four-part 
workflow:
1: Molecular pathological consultation
2: Pre-analysis technology
3: Molecular testing
4: Data acquisition, analysis and storage
These four parts are schematically illustrated in figure 4. The majority of molecular 
pathological consultations can be handled using high-throughput processes, while 
customized solutions are available for less frequent tests. The workflow is not 
static but is influenced by technological and biological demands, developments 
and improvements. New developments should be validated and implemented to 

































1: Molecular pathological consultation
The pathologist first decides which molecular pathological test to perform. 
Consultations for mutation hotspot analysis or extended mutation screening are 
frequent. Other consultations can be requested to detect genomic rearrangements 
and multi-gene or methylation-specific events. After a brief introduction to tumor 
genesis and general molecular principles, the different types of consultations for 
the detection of somatic mutations, multiple gene events, genomic rearrangements 
and methylation-specific events will be discussed.
Tumorigenesis
In essence, cancer is a genetic disease. Although certain cancers have specific 
unique characteristics, the development of human tumors is characterized by 
hallmarks that have been postulated and refined over recent decades. Mutations 
that affect oncogenes, tumor suppressor genes and tumor stability genes have 
been discovered, and these genes play an important role in tumor formation and 
progression [73–75]. 
Oncogenes and activated proto-oncogenes are characterized by a dominant gain 
of function and can have different origins. The first confirmed oncogene, Src, 
was discovered in 1976 by Bishop and Varmus, who received a Nobel Prize in 
1989 for their work. Src encodes a tyrosine kinase, and mutations in Src lead to 
the malignant progression of cancer [76,77]. Src inhibitors have been developed 
and are utilized to treat cancer patients [78]. The Philadelphia Chromosome is 
another early example of an oncogene and became an early example of the use 
of chromosome analysis for cancer diagnostics. This chromosomal abnormality 
was first described in 1960 when Hungerford and Nowell detected a tiny aberration 
in the chromosomes of cultured blood cells taken from two patients with chronic 
myelogenous leukemia [79]. The Philadelphia Chromosome is created by the 
translocation of the sections of chromosomes 9 and 22 that include the Abl and 
Bcr genes, respectively. The Bcr-Abl fusion gene formed by this translocation 
codes for a constitutively active receptor tyrosine kinase that causes uncontrolled 
cell proliferation. Research efforts led to the development of imatinib mesylate 
(Gleevec), which was the first in a new class of genetically targeted agents, a 
major advance in cancer treatment [80]. MYC is another proto-oncogene and has 
been implicated in Burkitt’s Lymphoma, named after Denis Parsons Burkitt, the 
surgeon who first described the disease in 1958 [81]. The MYC gene encodes a 
common transcription factor. In Burkitt’s lymphoma, patients have a chromosomal 
translocation that moves an enhancer sequence near the MYC gene, resulting in 
increased expression of this transcription factor [82]
Tumor suppressor genes are divided in gatekeeper genes and caretaker genes, 
based on their function and generally follow the hypothesis that both alleles of 
the gene must be affected for cancer to develop. This two-hit hypothesis was 
General Introduction
23 
formulated by A.G. Knudson while studying retinoblastoma [83,84]. There 
are exceptions to the “Knudson” model for tumor suppressors; for example, 
“dominant-negative” mutations in the TP53 gene produce a mutated p53 protein 
that inhibits the function of p53 produced by the wild-type allele [85]. Other 
exceptions to the Knudson model include tumor-suppressor genes that exhibit 
haploinsufficiency. In these cases, the level of one or multiple gene products 
is not sufficient for the cell to function normally. Haploinsufficiency of many 
genes, including APC, ATM, BRCA1, BRCA2, TP53, and RB, has been shown 
to contribute to tumorigenesis [86]. Gatekeeper genes such as APC, RB and 
TP53 inhibit tumor growth or promote tumor death. Inactivation of a gatekeeper 
gene often leads to tissue specific types of cancer such a Retinoblastoma or 
Adenomatous polyposis coli [87,88]. Caretaker or stability genes are another 
class of tumor suppressor genes, that promotes tumorigenesis in a different, 
more indirect way, when mutated [75,88]. This class includes the mismatch 
repair (MMR), nucleotide-excision repair (NER) and base-excision repair (BER) 
genes responsible for repairing mistakes that occur during DNA replication or 
that are induced by mutagen exposure. Consequently, mutations in this class of 
genes increase the mutation rate of other genes. Similarly to tumor-suppressor 
genes, both alleles of stability genes typically must be inactivated to produce an 
effect [75]. Examples of genes in this class include BRCA1, BRCA2, which have 
been implicated in breast cancer and MLH1, MSH2, PMS2, MSH6 and MUTYH 
in colon cancer. Many of these genes are currently being tested as molecular 
diagnostic markers.
Cancer cells can develop as a consequence of aberrations in these classes 
of genes. Eight different hallmarks of cancer cells have been postulated, and 
collectively they dictate malignant growth: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed cell 
death (apoptosis), limitless replicative potential, sustained angiogenesis, tissue 
invasion and metastasis, reprogramming of energy metabolism and evading 
immune destruction. Cancer cells do not act in isolation; rather, they subsist in a 
rich and heterogeneous microenvironment where the tumor stroma contributes 
to cancer initiation, growth and progression. All this should be considered in the 
molecular diagnosis and treatment of cancer [73,74,89]. 
Somatic mutations
Many examples are available to illustrate the need for somatic mutation analysis 
in patient care. For instance, mutations in the KRAS oncogene, codons 12, 13 
and 61 are frequently found in many cancers. Activating mutations in KRAS 
codons 12 and 13 are associated with resistance to TKIs in non-small-cell lung 
carcinoma (NSCLC) [90,91] and are used to predict resistance to monoclonal 
antibody therapy in colorectal cancer (CRC) [92,93]. A specific KRAS c.34G>T 
transversion may indicate a failure in the base excision repair mechanism in 
colon cancer due to germline mutations in the MUTYH gene [94]. 
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For BRAF, the V600E variant and the more rare V600K variant are found in 
the majority of cutaneous melanomas, and mutation-positive tumors can be 
treated with vemurafenib (PLX4032), which targets these molecules [95,96]. In 
papillary thyroid carcinoma (PTC), the V600E mutation appears to be refractory 
to radioactive iodine treatment, which consequently leads to a poor clinical 
prognosis [97,98]. However, initial studies have demonstrated that these thyroid 
cancers do not clinically react upon vemurafenib (PLX4032) treatment. Although 
reports indicate that the V600E alteration predicts resistance to monoclonal 
antibody therapy in colorectal cancer and NSCLC [90–93] , this knowledge has 
not been used clinically to date. 
Mutations in the PIK3CA gene may play an important role in CRC but have not 
been associated with specific therapies and are still under study [99]. The PIK3CA 
hotspot mutations E542K, E545K, H1047R are also reported in NSCLC [90,91].
Hotspot mutations in NRAS and HRAS are present in specific types of benign 
and malignant thyroid cancers. NRAS mutations in codon 61 are reported to be 
involved in tumor progression and a more aggressive clinical behavior of the 
tumor [97,98,100].
Specific mutations in GNA11 and GNAQ are found in uveal melanoma, which can 
be treated with MEK inhibitors [101]. 
Specific somatic heterozygous mutations in the isocitrate dehydrogenase genes 
IDH1 and IDH2 have been detected in the non-hereditary skeletal disorders Ollier 
disease and Maffucci syndrome and aid in the subclassification of these tumors 
[102]. Mutations in the IDH1 gene are also found in malignant gliomas and have 
been used to further evaluate the disease [103]
A subset of NSCLC cancers may harbor an activating mutation in the EGFR 
kinase domain [104]. Deletions in exon 19 and the L858R variant in exon 21 
are the most frequently found mutations, and tumors with these mutations are, 
in many cases, sensitive to tyrosine kinase inhibitors (TKIs). If the exon 19 and 
21 hotspot mutations in NSCLC are not present, Sanger sequencing can be 
performed on exons 18-21 to identify rare variants that may predict a favorable 
response to TKI inhibitors [90,91].
The majority of gastrointestinal stromal tumors exhibit oncogenic activating 
mutations in the v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
(KIT tyrosine kinase) and platelet-derived factor receptor α (PDGFRA) [105–
107]. In different types of melanomas, mutations in KIT exons 11, 13 and 17 are 
observed, and designer compounds, such as Imatinib, may offer an immediate 
therapeutic benefit for these patients [108]. 
Sanger sequencing of exons 5-8 in TP53 can predict if the tumor is metastatic 
or if a secondary primary tumor has emerged [107,109]. Beta-catenin (CTNNB1) 
analysis is performed in desmoid fibromatosis to establish differential diagnosis 
and prognosis. The most frequently found mutations are in exon 3 and serve as 
potential molecular tools for disease management [110].
Multiple gene events and genomic rearrangements 
Two major genetic mechanisms are frequently involved in CRC formation: the 
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chromosome instability (CIN) and microsatellite instability (MSI) pathways. 
Testing for CIN and MSI status can provide insight into the prognosis of the 
patient. In general, CIN+ and MSI+ cancers have worse and better prognoses, 
respectively [111–113].
The detection of 1p/19q chromosomal deletions has become essential for 
treatment decisions for cancer of the central nervous system. Oligodendrogliomas 
presenting with 1p/19q chromosomal deletions have favorable responses to 
chemotherapy and a substantially longer survival [103,114].
Other markers used in the evaluation of malignant gliomas are alterations in the 
epidermal growth factor receptor (EGFR) pathway and chromosomal deletions 
and amplifications in CDKN2A (p16), EGFR, ERBB2 (HER2), PTEN and TP53 
[114,115].
Chromosomal rearrangements also play an important role in the formation of the 
thyroid cancer variant PTC. The rearranged during transfection (RET) gene is 
a tyrosine kinase receptor located on chromosome 10 and is often found to be 
mutated in PTC. Thus far, 13 different types of RET/PTC rearrangements have 
been identified [116]. RET/PTC chimeric proteins lead to constitutive activation 
of the tyrosine kinase domain and other downstream pathways. Compounds that 
have an inhibitory effect on the kinase activity of RET have been identified and 
tested in multiple clinical trials [97,98,100].
Gene fusions, which occur due to specific chromosomal translocations, 
are observed in many soft tissue tumors, such as Ewing sarcomas. These 
rearrangements help to improve the diagnosis of a wide variety of sarcomas 
in children and young adults [117]. The fusion of anaplastic lymphoma kinase 
(ALK) with echinoderm microtubule-associated protein-like 4 (EML4) is present in 
approximately 5% of all NSCLC cases and has become a clinical target for ALK 
inhibitors [118].
Recently, more and different RET, ALK and ROS fusions have been identified 
in lung adenocarcinomas through whole-genome and transcriptome sequencing 
[119], targeted next-generation sequencing [120] and integrated molecular- and 
histopathology-based screening [121] and will most likely be identified as relevant 
clinical targets. 
Methylation specific events 
The inactivation of tumor-suppressor genes by DNA methylation in the promoter 
region of the gene is associated with a loss of expression and plays an important 
role in gene silencing. These effects are well recognized in carcinogenesis and 
can have diagnostic, prognostic and predictive value [122]. 
Hypermethylation of the MLH1 promoter can be used to subclassify sporadic 
colon cancer patients with a microsatellite instable (MSI) pattern from those with 
Lynch syndrome MSI tumors [111,123]. 
The methylation status of the O-6 methylguanine-DNA methyltransferase 
(MGMT) promoter is used to evaluate malignant gliomas [124]. Epigenetic 
silencing of MGMT augments sensitivity to temozolomide, which damages DNA 




The application of DNA methodology in tumor genetics and genomics has been 
hampered by two major factors. First, because the patient material is mainly 
used for microscopic examination and has to be prepared for long-term storage, 
almost all available patient material is formalin-fixed and paraffin-embedded . 
The fixation and embedding procedures leave cellular structures mainly intact 
but damage nucleic acids. Consequently, nucleic acid isolation is a challenging 
task and often yields heavily degraded DNA for use in further analyses. Second, 
due to early diagnosis and the use of novel neo-adjuvant patient treatments, the 
number of cases for which only very small amounts of material are available is 
increasing [15]. 
In this part of the workflow, the type of available material and how it must be 
processed must be defined before DNA can be isolated. In a minority of cases, 
high-quality DNA can be isolated from freshly frozen tumor samples, but generally, 
FFPE or cytological tissue is the primary source available for processing. The 
pathologist decides if tissue cores can be taken or if the isolation should be 
performed on tissue slices. If tissue slices are available, whether the whole slice 
can be used or if micro-dissection is necessary, should be determined. After 
isolation, the quality and quantity of the isolated DNA should be assessed to 
determine if it is sufficient to perform the next steps in the process. In some 
cases, the DNA has to be diluted, concentrated or treated with a whole genome 
amplification step. Material preservation, micro-dissection, DNA isolation, whole 
genome amplification and DNA quantification will be discussed further.
Tissue preservation
Fresh or freshly frozen materials are the best sources for the extraction of nucleic 
acids and protein. However, for the microscopic analysis of tissue slices, FFPE 
material has been used for over a century in daily pathological practices [125]. 
Storage of FFPE tissues is inexpensive, and the embedded tissue can be kept 
almost indefinitely at room temperature. Therefore, laboratories with pathological 
archives have endless amounts of FFPE tissue samples [125,126].
Tissue fixation is commonly achieved by the addition of a 4% aqueous solution 
of buffered formaldehyde [127]. However, in some tissue types, additional or 
pretreatment steps must be performed [128,129]. Unfortunately, in this process 
of fixation and embedding, chemical crosslinking between RNA, DNA and protein 
occurs. Together with the addition of monomethylol groups to nucleotide base 
pairs, the quality of the nucleotides in the tissue is diminished. Only degraded and 
short fragments of the DNA and RNA remain for use in molecular analyses [130]. 
Microdissection versus macrodissection 
For pathological examination of FFPE material, tissue sections are cut from 
tissue blocks. The sections are stained with hematoxylin, which stains the 
cell nuclei blue, and eosin, which stains the cytoplasm and other extracellular 
substances red or pink. There are different methods for further processing the 
material to make it suitable for molecular testing. For solid tumors, it is likely that 
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tumor cells are present in high concentrations, making it possible to use whole 
tissue sections or tissue cores for DNA extraction. However, in the presence of 
abundant stroma and other normal cells, the tumor cells may be obscured, making 
these samples more difficult for specific DNA or RNA analysis. To circumvent 
this complication, tumor cell enrichment strategies, such as cell sorting, laser 
capture microdissection or manual microdissection, can be performed. With 
these methods, the tumor epithelium is separated from the surrounding stroma 
and healthy tissue [131,132].
In laser capture microdissection (LCM), a transparent thermoplastic film or 
other coating is applied to the surface of a tissue section on a glass slide. A 
laser pulse then specifically activates the film above the cells of interest, and 
consequently, a strong focal adhesion permits the selective procurement of the 
targeted cells [133,134]. LCM can process very tiny amounts of pure tumor cells, 
but unfortunately, this method is time consuming and labor intensive. Therefore, 
in many routine settings, manual microdissection is performed with a scalpel 
blade. In this method, guided by an H&E-stained slide, tumor fields are scratched 
from deparaffinized, hematoxylin-stained copies of the original tissue slice. If very 
little material is present, which is often the case in cytological smears of the lung, 
microdissection is initiated by marking the tumor foci with a diamond needle on 
the back of a H&E- or Giemsa-stained slide. The cover slips are removed by 
soaking the slides in xylene. Finally, the tumor foci are collected with a scalpel 
blade [135] [136].
DNA isolation
The isolation procedure begins with the deparaffinization of the tissue, which 
is a time-consuming step in most protocols and is often performed by xylene 
incubation followed by ethanol washing steps [137,138]. Several methods have 
been described to isolate DNA after deparaffinization. The majority of the methods 
require manual isolation steps, although some (semi-) automated methods have 
been described. Column- or bead-based methods are most commonly used 
[139–141]. The quality and quantity of the DNA obtained with these different 
techniques is variable, and the final DNA yield can be low and of reduced quality. 
The type, quality or quantity of the input material contributes to the DNA yield, but 
the isolation method can also play an important role [142,143].
Whole genome amplification
To obtain sufficient DNA for further molecular testing, additional steps, such as 
whole genome amplification (WGA) or other pre-amplification steps, may be 
necessary [144,145]. WGA ideally generates a new whole genome sample of 
amplified DNA (wgaDNA) that is indistinguishable from the original sample but 
contains a higher DNA concentration [142]. There are two types of WGA: WGA 
based on PCR and WGA with non-PCR-based linear amplification [146]. The 
major disadvantage of all WGA methods is that ideal conditions do not exist. De 
novo mutations can be introduced, and parts of the genome can be preferentially 
under- or over-represented in the wgaDNA due to GC content or repetitive 
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sequences. The introduction of de novo point mutations should be considered, 
particularly when performing further DNA tests, and wgaDNA should not be used 
in single nucleotide hotspot mutation analysis [147]. Some WGA methods require 
high molecular weight DNA. An example is the strand displacement amplification 
method (SDA), which is based on rolling circle amplification [148]. Primer 
extension pre-amplification methods have been more successfully applied to 
FFPE tissue because these methods can better accommodate fragmented DNA 
[149,150].
DNA quantification
Different methods are available to measure the quality and quantity of the isolated 
or amplified DNA. One method is to perform a spectrophotometric measurement 
using a NanoDrop® instrument. In this approach, the ratio of the absorbances 
at 260 nm and 280 nm is used to assess the purity of the DNA. A ratio of ~1.8 is 
generally accepted as “pure” for DNA. Little material is needed, and the method 
can be performed rapidly. However, the measured DNA concentration may be 
an overestimate because all DNA fragments, even if partly degraded, give a 
fluorescent signal. Additionally, ionic strength and pH can influence the estimated 
DNA concentration [151]. Nanodrop analysis is mainly used to measure the 
concentration of amplified DNA. If heavily degraded DNA isolated from FFPE 
material is measured, the DNA concentration can be overestimated, leading to the 
failure of downstream applications. In this situation, more accurate approaches 
should be used. This can be achieved by making use of an intercalating dye 
such as PicoGreen®. This dye is essentially non-fluorescent and will only exhibit 
fluorescence after binding to double-stranded DNA. A high linearity is achieved, 
and dsDNA concentrations can be deducted by making use of a standard 
curve [152]. Therefore, PicoGreen-based assays are preferred for quantitative 
measurements of DNA extracted from FFPE material over spectrophotometric 
approaches in which no, or limited, information is gained on the quality of the 
DNA. An apparently highly concentrated sample may be composed of heavily 
degraded DNA and short DNA fragments, while a sample with an apparently 
low DNA concentration may be composed of longer and better quality DNA. 
Consequently, the best way to gain insight into the quantity and quality of the DNA 
may be to perform “quality” PCR. In this approach, amplicons located on different 
loci in the genome and of different lengths (for instance, 100, 200 and 400 base 
pairs) are generated and further analyzed on an agarose gel or by real-time PCR, 
making use of threshold cycles (Cq) and melting curve profiles. The longer the 
fragments generated, the higher the quality of the DNA, and this can be taken into 
account when making DNA dilutions for genetic testing [153,154]. Alternatively, 
capillary electrophoresis using LabChip instruments, such as the low-throughput 
Agilent 2100 Bioanalyzer and the high-throughput Caliper LabChip GX can be 
used to give both qualitative and quantitative information about the samples. The 
Life technologies Qubit® 2.0 Fluorometer, used in combination with Molecular 
Probes® dyes or methods, is another alternative; it makes use of fluorescent 
dyes specific for non-degraded nucleic acids. 
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3 and 4: Molecular testing, data collection, analysis and storage
In the third part of the workflow, molecular testing is performed. Mutations can 
be detected with closed-tube (real-time) PCR technology and different types of 
low-throughput sequencing. Copy number and chromosomal rearrangements 
can be detected with more complex technologies such as multiplex ligation-
dependent probe amplification (MLPA), CGH and SNP arrays. High-throughput 
sequencing technology can be used to combine mutation screening with 
chromosomal rearrangement analysis. In the fourth and last part of the workflow, 
all of the acquired data are processed and analyzed using dedicated software 
or specialized analysis tools. The analyzed data are linked to the clinical and 
pathological information of the patient. After a careful process of analysis and 
quality evaluation in a diagnostic setting, the final results are reported to the 
clinic. In a research setting, the data can be further processed and analyzed 
to answer biological hypotheses. In this section, different methods for somatic 
mutation detection and prescreening, including hydrolysis probe assays and high 
resolution melting and sequencing, will be presented. Copy number variation 
assays with MLPA and SNP arrays will be discussed, and high-throughput next-
generation sequencing will be introduced. 
Somatic mutation detection and analysis
Over the years, many different techniques have been developed and used in 
research and diagnostics to detect somatic mutations. Most of these techniques 
are based on PCR. Hotspot mutation analysis can be performed with hydrolysis 
probe assays [136], Matrix-assisted laser desorption ionization Time of Flight 
(MaldiToF) [155], SNPshot [156] and pyrosequencing [157]. For mutation 
scanning, Sanger sequencing, although it’s sensitivity is limited to 10-20% for 
somatic mutations, remained for long the gold standard [158]. To accelerate the 
process and reduce costs, many types of prescreening methods can be applied. An 
example of prescreening methodology is high-resolution melting analysis (HRM 
or HRMA) [142], which can be used in combination with COLD-PCR [159]. Other 
examples include denaturing high-performance liquid chromatography (DHPLC) 
[160], conformation-sensitive gel electrophoresis (CSGE) [161] and single-
strand conformational polymorphism detection (SSCP) [162]. High-throughput 
next-generation sequencing (HT-NGS), massive parallel sequencing and third-
generation sequencing are all different terms for the methodologies developed 
over the last decade. These techniques have greatly increased sequence 
throughput while decreasing costs [163,164]. The first generation of HT-NGS 
platforms delivered 100 Mb (Roche 454 Genome Sequencer) to 3 Gb (Illumina 
Solid Genome Analyzer) of sequence data per run [165]. Since the introduction of 
HT-NGS, sequencing chemistry and hardware has rapidly improved. New small 
bench-top sequencers have been developed with simple sample preparation 
protocols and the potential for faster data generation and analysis, making them 




Real-time quantitative PCR permits the sensitive, specific and reproducible 
quantitation of nucleic acids [166] and can be used in high-throughput, automated 
technologies with lower turnaround times [167]. Some of the various real-time 
PCR chemistries use the double-stranded DNA-intercalating agent SYBR® 
Green 1, while others use hydrolysis probes, dual hybridization probes, molecular 
beacons or scorpion probes [168]. To detect hotspot mutations, the hydrolysis 
probe method is frequently used. This method is often referred to as the “TaqMan” 
assay, but this is a brand name. Concerning the chemistry of this method, the 
Expert Review of Molecular Diagnostics states, “In the real-time quantitative 
TaqMan® assay, a fluorogenic nonextendable ‘TaqMan’ probe is used. The probe 
has a fluorescent reporter dye attached to its 5´ end and a quencher dye at 
its 3´ terminus. If the target sequence is present, the fluorogenic probe anneals 
downstream from one of the primer sites and is cleaved by the 5´ nuclease activity 
of the Taq polymerase enzyme during the extension phase of the PCR. While the 
probe is intact, FRET occurs, and the fluorescence emission of the reporter dye 
is absorbed by the quenching dye. Cleavage of the probe by Taq polymerase 
during PCR separates the reporter and quencher dyes, thereby increasing the 
fluorescence from the former. Additionally, cleavage removes the probe from 
the target strand, allowing primer extension to continue to the end of template 
strand, thereby not interfering with the exponential accumulation of PCR product. 
Additional reporter dye molecules are cleaved from their respective probes with 
each cycle, leading to an increase in fluorescence intensity proportional to the 
amount of amplicon produced.” [168] 
Real-time PCR data acquisition is performed using the software provided with 
the real-time PCR equipment. These analysis platforms are often too basic for 
further data analysis, and additional dedicated software is required. For instance, 
to analyze expression data, Vandesompele developed the widely used tool 
“Genorm” [169]. The analysis of real-time SNP-type data is easier to perform. 
However, dedicated approaches must be used if multiple variations on the same 
locus are interrogated (this thesis). A very important development in real-time 
PCR analysis is the effort to come to a worldwide consensus on how best to 
perform and interpret quantitative real-time PCR (qPCR) experiments. This 
developments led to the drafting of a list of guidelines, the Minimum Information 
for Publication of Quantitative Real-Time PCR Experiments (MIQE) [170]. 
High Resolution Melting 
HRM is a fast and simple alternative method for hydrolysis probe assays and 
mutation scanning in general [171]. This method is based on the principle that 
heating DNA results in the transition of the double-stranded DNA molecule into its 
two single strands. This process can be accurately monitored by measuring the 
fluorescence after the addition of a saturating DNA dye to the PCR reaction and 
after increasing time points and decreasing temperature units in an instrument 
with improved temperature precision [172]. A review by Erali et al. describes the 
main advantages of this method: “Simultaneous genotyping with one or more 
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unlabeled probes and mutation scanning of the entire amplicon can be performed 
at the same time in the same tube, vastly decreasing or eliminating the need for 
re-sequencing in genetic analysis.” [173]
The analysis of HRM data depends on the instrument used and consists of one 
or two normalization steps. First, the fluorescence (Y) axes of HRM plots are 
normalized on a 0 to 100% scale. In the next, optional step, normalization to the 
temperature (X) axis can be applied to compensate for well-to-well temperature 
measurement variations between samples. Finally, the different genotypes can 
be identified by plotting the difference in fluorescence between the normalized 
melting curves. One melting curve is chosen as a reference, and the difference 
between each curve and the reference is plotted against temperature to yield a 
“fluorescence difference” plot. The original reference curve is a horizontal line at 
zero, and the different genotypes are clustered along different paths [171].
Sanger DNA sequencing
Sanger DNA sequencing has been one of the most widely used molecular 
techniques because it provides direct insight into the molecular composition 
of the material under investigation and can be easily automated. Sanger 
sequencing is based on the synthesis of a complementary copy of a single-
stranded DNA template. To perform a sequencing reaction, a buffered mixture 
of DNA polymerase, a template-specific oligonucleotide, deoxynucleotides and 
fluorescently labeled dideoxynucleotides is added to the single-stranded DNA 
template. After cycling, DNA copies of various lengths are formed from the original 
template. The length of the products is determined by the position at which a 
fluorescent dideoxynucleotide is incorporated in the strand [31]. After capillary 
electrophoresis, the different length products are visualized and further analyzed 
with dedicated sequence analysis software. Mutation Surveyor, PolyPhred 
Sequencher and Sequence Pilot are commercial packages, but freeware for 
basic (Chromas, FinchTV) or more advanced sequence analysis (InSNP) can 
also be used [174]. It is important that the software can detect somatic mutations 
in cancer, which are often obscured as a consequence of tumor heterogeneity or 
the presence of excess normal DNA in the isolates. In addition, it is essential that 
information on mutations and variations in the human genome is communicated 
in a uniform way. In an effort to clarify the nomenclature, the Human Genome 
Variation Society (HGVS) has formulated guidelines and recommendations for 
gene variation nomenclature and variation databases [175–177]. Sequence 
variants in multiple genes per patient can be stored in a patient information 
system or database dedicated to the storage of gene variants, such as the Leiden 
Open-Source Variation Database (LOVD) [178,179].
Copy number variation detection and analysis
A number of methods can be used to detect copy number variation. A distinction 
can be made between methods that interrogate only one or a few loci and methods 
that can be applied for copy number variation analysis of the whole genome. 
Fluorescence in situ hybridization (FISH) and loss of heterozygosity (LOH) typing 
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with microsatellite markers are used to detect chromosomal imbalances in a 
single locus. To interrogate up to 50 different loci, multiplex ligation-dependent 
probe amplification (MLPA) can be performed. Genome-wide high-throughput 
methods, such as array-based comparative genome hybridization (array CGH) 
and single nucleotide polymorphism arrays (SNP arrays), have been applied in 
cancer research and diagnostics [72,180,181]. New developments in this field 
include the introduction of digital PCR for a single locus and high-throughput 
sequencing for whole genome-based copy number variation testing [182,183]. 
The use of MLPA and SNP array genomics will be discussed in more detail.
Multiplex ligation-dependent probe amplification 
The MLPA technique was first described in 2002 [184] and has become a multiplex 
technique for determining the copy numbers of genomic DNA sequences and 
promoter methylation status, as well as for mRNA profiling [185]. MLPA is a PCR-
based approach that is sufficiently sensitive, reproducible and sequence-specific 
and allows the relative quantification of up to 50 different targets simultaneously. 
MLPA is relatively easy to perform with standard laboratory equipment, a PCR 
instrument and a capillary sequencer. In MLPA, probes, not sample nucleic 
acids, are subject to amplification and quantification. Each locus is interrogated 
with two MLPA probes, which hybridize to adjacent sites of the target sequence. 
One probe is a short synthetic oligonucleotide, and the other is an M13-derived, 
long oligonucleotide. The short probe contains a target-specific sequence (21–
30 nucleotides) and a 19-nucleotide sequence at the 5’ end that is identical to 
the sequence of a labeled PCR primer. The long MLPA probe contains 24–43 
nucleotides of target-specific sequence at the 5’ phosphorylated end, a 36 
nucleotide sequence that contains the complement of an unlabeled PCR primer 
at the 3’ end, and a stuffer sequence of variable length in between. This variable-
length fragment gives each complete probe the necessary size difference for 
detection and quantification using capillary gel electrophoresis [184]. When 
both probes are stably hybridized to adjacent sites of the target sequence, they 
are ligated by a specific ligase enzyme, permitting subsequent amplification. 
MLPA probes are identified after capillary separation by size using a selected 
size standard for the size calling procedure. The relative MLPA probe signals 
(fluorescent units) reflect the relative copy number of the target sequence. An 
indication of the DNA input in the MLPA reaction may be obtained by examining 
the dosage quotient (DQ) control fragments, fragments whose lengths always 
co-vary and are present in all MLPA kits. The signals of these fragments will be 
prominent if the amount of sample DNA is very low. By contrast, the fifth control 
band of 92 nucleotides is ligation-dependent and should have a signal similar 
to most of the other MLPA amplification products. Visual inspection of the peak 
pattern of a patient sample superimposed over a peak pattern of a reference run 
can be used to analyze a few samples [185].
The analysis of a larger series of samples, more complex diseases and MLPA 
runs performed with miscellaneous sample types and quality requires exportation 
of the peak signals and reliable normalization methods. Statistical methods 
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must be applied to identify probes that show aberrant copy numbers. Analysis 
overviews must be made available before the method can be applied in molecular 
diagnostics [186–188].
SNP arrays
 Different methodologies of SNP typing and types of commercially available SNP 
arrays have been developed. Basically, two types of arrays exist: arrays with 
universal capture oligonucleotides or locus-specific arrays of oligonucleotides. 
The SNP typing assays include methodologies such as allele-specific primer 
extension and whole genome sampling. Two different genotyping methods, 
molecular-inversion probe (MIP) genotyping and GoldenGate genotyping, are 
based on high-level multiplex PCR with universal primers in combination with 
universal arrays.
Molecular-inversion probe (MIP) genotyping arrays are commercially offered as 
Affymetrix OncoScanTM arrays. MIP genotyping utilizes a pool of locus-specific 
probes. The 5’ and 3’ ends of each circularizable probe anneal upstream and 
downstream of the SNP, respectively. The 1 bp gap is filled in a different reaction 
for each nucleotide. The probes are subsequently circularized using ligase to 
seal the remaining nick, and non-annealed and noncircular probes are removed 
by exonuclease treatment. Restriction digestion then releases the circularized 
probe, and the resulting template is PCR-amplified using common primers [189]. 
The reactions for each of the four nucleotides are labeled in different colors and 
pooled. Subsequently, the pool is hybridized to an array of universal-capture 
probes, and the four colors are read. With MIP arrays, the entire genome can 
be interrogated with more than 335,000 markers using 75 ng DNA isolated from 
FFPE tissue [190,191].
GoldenGate genotyping makes use of a multiplex mixture of probes for 96, 384, 
768 or 1536 SNPs per array [192]. For each SNP, a combination of allele-specific 
and locus-specific primers are annealed to the SNP locus. These primers are 
tailed with common forward and reverse primers and a universal capture probe 
that is complementary to the locus-specific primer. The small gap between 
the allele and locus-specific probes is filled by allele-specific primer-extension 
and sealed with a ligase, resulting in an artificial allele-specific PCR template. 
This template is then PCR amplified using fluorescently labeled universal PCR 
primers. The resulting probe is hybridized to an array of universal-capture probes, 
and the array is scanned in a special reader, generating two fluorescent signals 
that represent the two different alleles of a SNP. 
Locus-specific arrays of oligonucleotides, such as Affymetrix GeneChips, can 
detect over one million SNPs on a single chip. For instance, the Genome-Wide 
Human SNP Array 6.0 features 1.8 million genetic markers, including more than 
906,600 single nucleotide polymorphisms (SNPs) and more than 946,000 probes 
to detect copy number variation. For each SNP, a set of locus-specific 25-mer 
oligonucleotides is present on the array. The sample is prepared according to the 
whole-genome sampling assay [193], a method in which the genomic complexity 
is reduced through restriction enzyme (RE) treatment of high-quality genomic 
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DNA and ligation of a common adaptor to the digested DNA. The subsequent 
single-primer PCR step reduces the genomic complexity through efficient size-
selection in the PCR reaction. The product is then hybridized to a locus-specific 
array. The SNPs on the array are selected from the DNA that is represented after 
the complexity reduction PCR step [194]. 
Illumina Infinium arrays are locus-specific arrays with allele-specific capture 
probes. In this assay, whole-genome DNA is amplified and subsequently 
fragmented. The resulting probes are then denatured and hybridized to the array. 
An ‘on the array’-allele-specific primer extension assay is followed by staining and 
read using standard immunohistochemical detection methods [195]. This type of 
array is available for genotyping, copy number variation (CNV) and cytogenetic 
analysis and consists of 300,000 to nearly 1.2 million markers.
After scanning the SNP arrays, the signal intensities must be converted into 
genotype calls. SNP calling software is available for each platform: BeadStudio 
for GoldenGate and Infinium, GTYPE and Genotyping Console for GeneChips, 
and GTGS for the MIP assay. All programs are essentially similar with 
three clusters automatically computed for each SNP: heterozygous AB and 
homozygous AA or BB. The clusters are based upon the allele-specific signal 
intensities. Genotyping errors and no-calls will hamper linkage and association 
studies, and reliable SNP calls are essential for these applications. Therefore, 
additional genotyping algorithms have been developed to improve the quality of 
the genotypes from SNP arrays. Examples of these methods are SNIPer [196] 
AccuTyping [197], SNPchip [198] and RLMM [199]. GTC software is available 
for the simultaneous analysis of SNPs, copy number polymorphisms (CNPs), 
rare copy number variations (CNVs) and cytogenetic aberrations (http://www.
affymetrix.com/, accessed January, 2013). For sensitive analysis of copy number 
variation in tumors, BeadarraySNP, a Bioconductor package was introduced for 
the analysis of Illumina SNP array data. An algorithm, the lesser allele intensity 
ratio (LAIR), was developed to accurately determine allelic (im)balances. Further 
incorporation of the ploidy status of the tumor permits the identification of the 
allelic state of all chromosomal aberrations, including LOH, copy-neutral LOH, 
balanced amplifications and allelic imbalances. For the validation series, 300 k 
CytoSNP-12 (Illumina, USA) high-density SNP arrays were used [72]. 
High Throughput Next Generation Sequencing (HT-NGS)
With the current technological advances in next-generation sequencing, the 
simultaneous sequencing of hundreds of candidate genes up to the whole exome 
[34], the transcriptome [37,200], the epigenome [201] and the whole genome 
[202] has recently become feasible. HT-NGS technology provides the opportunity 
to identify previously unknown cancer-predisposing genes or somatic mutations in 
individual patients, families and tumors [203,204]. For instance, the identification 
of novel genes that predispose patients to colorectal cancer could be directly 
implemented in clinical practice. In clinical genetics centers, the knowledge of 
disease-related genetic mutations could be used for counseling and to advise the 
surveillance of these mutations in families. The identification of at-risk individuals 
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will result in timely and efficient customized surveillance through colonoscopy. 
Furthermore, these gene mutations may provide therapeutic leads to improve the 
treatment of cancer.
Commonly used second-generation HT-NGS platforms include the Roche 454 
Genome sequencer, the Illumina Genome Analyzer and the Applied Biosystems 
SOLiD system [34]. These instruments are based on the massive parallel 
sequencing of spatially separated clonal amplicons [163]. They are mainly 
used to target thousands of genes in one or a few samples from which as much 
sequence as possible is retrieved, with the disadvantage of long runtimes of up 
to two weeks. In molecular tumor diagnostics, the demand will most likely be 
focused on the rapid sequencing of smaller subsets of genes in multiple samples 
with sufficient sequence depth to identify rare somatic variants in heterogeneous 
tumors. This demand can be met by using a combination of smaller, faster, bench-
top sequencers in combination with the targeted sequencing of “DNA barcoded” 
samples. Instruments such as the 454 GS Junior (Roche), MiSeq (Illumina) and 
Ion Torrent PGMTM or ProtonTM (Life Technologies) are currently available for this 
purpose and will likely have a decisive impact on diagnostics in the near future 
[205]. DNA barcoding can be achieved by adding unique tags to the ends of DNA 
fragments. These tags can be linked to the DNA during PCR or after the isolation 
of targeted sequences [34,206,207]. Targeted sequencing can be performed with 
customized panels, such as the Ion AmpliSeq™ Target Selection Technology, 
or dedicated “cancer panels”, such as the Ion AmpliSeq™ Cancer Panel, which 
promises to assess hundreds of mutations in 10 ng of FFPE-DNA in a single day 
(http://www.lifetechnologies.com, accessed January, 2013). Another method that 
is likely suitable for this strategy was developed in Uppsala, Sweden and was first 
described in 2005 [208]. This method, the HaloPlex™ target enrichment system, 
was adapted by Agilent and is based on the digestion of DNA with different sets 
of restriction enzymes (http://www.agilent.com, accessed January, 2013). The 
targeted nucleic acid sequences are hybridized with oligonucleotide constructs 
called selectors. The selectors contain target-complementary end-sequences 
that are joined by a general linking sequence and that act as ligation templates 
to direct the circularization of target DNA fragments. Circularization only takes 
place if a ligation reaction has occurred, which makes the method theoretically 
very sensitive and specific. Only these circularized targets are then amplified 
in multiplex using one universal PCR primer pair that is specific for the general 
linking sequence in the selectors. By combining selector technology with high-
throughput parallel sequencers, rapid resequencing can be accomplished from 
multiple genes and multiple specimens if DNA barcoding is applied [34,208]. 
A collaboration between Agilent Technologies and the LUMC Department of 
Pathology was initiated in 2011 to investigate the possibility of using this method 
for FFPE material; the performance of the method was determined by comparing 
DNA isolated from freshly frozen tumors with DNA from formalin-fixed and 
paraffin-embedded material isolated from the same tumor. The initial results are 




Considerations in Molecular Pathology.
The role of the pathologist and his laboratory team has changed dramatically 
over time. After centuries of organ-based pathology that provided little benefit to 
patients, the field moved in the mid-nineteenth century to cellular-based clinical 
pathology with the potential to improve diagnosis and tumor classification, and, 
currently, the molecular pathologist plays an important role in ‘personalized 
medicine’.
A pathologist has been described as the following: “a physician, concerned 
with human suffering and willing to make a considerable effort to decrease 
this suffering; a scientist with an inquiring mind, using advanced tools to study 
disease; an educator, sharing his knowledge, scientific inquiry methods and spirit 
with his students and other medical colleagues; and a leader in both pathology 
and medicine because he believes in quality assurance and the role of pathology 
in the overall advancement of medicine”. Because of their multiple roles, 
pathologists continually build bridges between clinical medicine, surgery and 
basic science [209]. Microscopic tissue anatomy guides the initial classification 
of disease. Immunohistochemistry enables proteins to be visualized in tissue and 
facilitates the determination of the origin and nature of normal and aberrant cells. 
Developments in molecular biology improve the ability to examine the functional 
and genetic qualities of tissues, leading to better classification, diagnosis and 
treatment of disease [9]. 
Important aspects of molecular pathology must be further developed because 
the criteria and processes for implementing a molecular diagnostic test as the 
“standard-of-care” in a clinical setting have not been fully established. The 
following must be considered: resourcing appropriate patient material, assay 
development and supply, quality control, reporting and auditing, ethical and 
regulatory elements such as reimbursement and the role of the pharmaceutical 
industry [210]. With these considerations, it should be possible to develop a 
system that works locally to balance the increasing demands for higher quality 
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Preoperative biopsies or imbedded cytological cells will become more and more 
a primary source of tissue for molecular diagnostic analyses as a result of novel 
neo-adjuvant treatment regimens for several cancer types. Furthermore there 
is a growing need to examine metastatic cancer tissue. Hence, nucleic acids 
need to be reliably isolated and analyzed from small amounts of formalin-fixed 
and paraffin-embedded (FFPE) tissue. The limited numbers of (tumor) cells in 
these samples make high quality and sensitive DNA isolation challenging. Also 
demands for faster turnaround times are growing. Therefore, we evaluated a fully 
automated DNA/RNA isolation system and compared this with a manual, classical 
routine molecular pathology method. We compared the quality of the isolates 
from both tissue cores and micro-dissection for detection of hotspot mutations 
in KRAS, BRAF applying hydrolysis probe assays. In addition we determined 
whether the automated method decreases the hands-on-time and turnaround 
times in routine molecular pathology workflow.
In conclusion, the automated method delivers high quality DNA from both 
small FFPE tissue cores and micro-dissected tissue material. In comparison to 
classical methods, less than 50% of starting tissue was sufficient as input for 
micro-dissection. Turnaround times decreased significantly and 50% less hands-
on time was needed.
Introduction 
Increasing numbers of cancer biomarkers have been implemented in molecular 
tumor diagnostics worldwide [1–4]. Mutations in KRAS predict for resistance to 
monoclonal antibody therapy in colon cancer patients [5]. In BRAF, the V600E 
and the rarer V600K variant are found in the majority of cutaneous melanoma, 
making the patients eligible for treatment with vemurafenib (PLX4032). [6] A 
subset of Non_Small_Cell_Lung_Cancers may harbour activating mutations in 
the EGFR kinase domain and might thereby respond to certain tyrosine kinase 
inhibitors [2]. Thus, based on these test results for KRAS, BRAF and EGFR, 
patients may be selected for guided treatment. Furthermore, a delay in the start 
of treatment of a cancer patient might influence the patient’s life expectation (e.g., 
for the treatment of lung cancer with tyrosine kinase inhibitors). In addition, the 
amount of cancer material that is available for testing is decreasing as a result 
of the introduction of neo-adjuvant treatment protocols and the growing need to 
examine metastatic cancer tissue. Less invasive sampling procedures [7] may 
lead to little amounts of material. 
The starting point in biomarker testing in pathological specimen is the efficient 
isolation of nucleic acids. These can be isolated from formalin-fixed, paraffin-
embedded (FFPE) tissue from whole tumor sections, micro-dissected material, 
tissue cores or imbedded cytological material [8,9]. In FFPE tissue DNA 
degradation has already taken place resulting in a negative contribution to the 
quantity and quality of the DNA. [10,11] Several manual and semi-automated 
methods have been described for DNA extraction from FFPE tissue [12,13]. DNA 
quality and quantity obtained with these different techniques is variable. This 
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variability is primarily due to the quality of the material that has been used and not 
because of the quality of the isolation technique [14]. Nevertheless, all techniques 
described thus far require many hours of hands-on time and include operator- to-
operator variation that might contribute to less reproducible and robust results 
[15]. Part of the hands-on time is due to the manual micro-dissection and lysis 
of the tumor tissue. However, deparaffinization is a crucial, time consuming step 
that can impact the quality and quantity of the extraction [16]. Moreover, this 
process often includes the use of toxic reagents such as xylene [17]. Additionally, 
in many cases, and specifically in micro-dissection, the final DNA yield is low 
and of reduced quality, thereby requiring additional steps such as whole genome 
amplification or other pre-amplification steps in order to obtain sufficient DNA for 
further molecular testing. [18–20]. Therefore, there is an increasing demand for 
fully automated, optimized and time-saving methods for the high quality DNA 
extraction from limited amounts of material.
Here we describe DNA extraction using a fully automated DNA/RNA extraction 
system which can process 48 tissue samples in 3 hours 15 min using silica-coated 
magnetic nanoparticles. The process integrates both lysis and deparaffinization 
by hydrophobic adsorption instead of offline xylene based deparaffinization 
[21,22]. We investigated if the quality of the isolated DNA from tissue cores and 
micro-dissected tissue obtained with this newly described method compares to 
our classical method. We also evaluated if the method decreases the turnover 
(turnaround) time for our most common molecular assays. 
We determined that the fully automated method delivers high quality DNA from 
small tissue cores and micro-dissected material as compared to our classical 
method. For micro-dissection we found that only 20%- 50% of starting material 
was needed for the fully automated method when compared to the classical 
method. When the DNA is used in hydrolysis probes assays we achieved 24 hours 
faster turnover (turnaround) time with 50% less hands-on time being required. 
Material and Methods 
ETHICS STATEMENT
All samples used in this study were handled according to the medical ethical 
guidelines described in the Code Proper Secondary Use of Human Tissue 
established by the Dutch Federation of Medical Sciences (www.federa.org, 
accessed October 27, 2010). According to these guidelines, the specific need 
for the ethics committee’s approval was not necessary for this study because all 
human material used in this study has been anonymized. 
TEST MATERIAL
This study included formalin-fixed, paraffin-embedded tissue samples obtained 
from micro- dissected tissue from slides (10 µm) and tissue cores (0.3 mm 
diameter and variable length) of different tissue types (Supplementary table 1). 
Hematoxylin-eosin staining was performed on tissue sections to visualize presence 
of tumor cells. These were used to guide micro-dissection on hematoxilin-stained 





Classical DNA extraction from FFPE material was performed according to the 
method described by de Jong [23]. In brief, the FFPE sections on slides or tissue 
cores were deparaffinized by two xylene and ethanol washing steps (process 
includes centrifugation and incubation steps as well). The sections and cores 
were collected in various amounts of PK1 buffer depending on the amount of 
material and then incubated overnight at 56°C in the presence of proteinase K 
and Chelex beads. If the volume of the PK1 buffer was under 15 µl no Chelex 
beads were added. The following day the samples were further incubated at 
100°C for 10 minutes, centrifuged and then the supernatant was transferred to a 
clean tube.
The fully automated method
The fully automated DNA extraction from FFPE tissue (Tissue Preparation 
System with VERSANT Tissue Preparation Reagents, Siemens Healthcare 
Diagnostics, Tarrytown, NY) has been described previously, [21,22] In this 
method micro-dissected tissue or tissue cores were directly transferred into 1.5 
ml tubes (Sarstedt, Nümbrecht, Germany) and subjected to automated total 
nucleic acid extraction. Samples were heat lysed in 150-µL FFPE buffer at 80oC 
for 30 minutes with shaking. After cooling, enzymatic lysis was carried out at 65oC 
for 30 minutes with proteinase K. Any residual tissue debris was then removed by 
the nonspecific binding to silica-coated iron oxide beads followed by subsequent 
magnetic separation. Deparaffinized and clarified lysates were transferred to 
new tubes and nucleic acids were bound to fresh silica-coated beads under 
chaotrophic conditions. Beads were washed 3 times and total nucleic acids were 
eluted with 100 µL of elution buffer at 70oC.
MOLECULAR ANALYSIS
Hydrolysis probes assays were performed as described elsewhere [7]. In this 
method 10µl qPCR reactions contained 5µl mastermix (FastStart Universal 
Probe Master, Roche Diagnostics, Almere, The Netherlands), 1µl of 10x primer 
and hydrolysis probe solutions and 2µl DNA solution or sterile water. qPCR was 
performed in a sealed 384 well plate in a qPCR instrument (CFX384, Bio-Rad, 
Veenendaal, The Netherlands), with an initial denaturation step of 10 minutes 
at 95°C follow by 40 cycles of 15 seconds at 92°C, 60 seconds at 60°C and 10 
seconds at 72°C. In the experiments described below we used 8 different assays, 
7 for KRAS p,G12S, p,G12R, p.G12C, p.G12D, p.G12A, p.G12V and p.G13D 
and one for the BRAF p.V600E variant. 
Results 
For molecular diagnostic analyses of hotspot mutations in KRAS and BRAF 
on DNA isolated from small tissue cores or micro-dissected tissue sections 
hydrolysis probes assays are often used.. As described, DNA isolation from 
FFPE tissue sections is possible with a fully automated system in the routine 
laboratory [22,24]. Since in our laboratory we isolate DNA in ~ 60% of the cases 
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from tissue cores, our first assessment of the fully automated system was to 
determine if DNA could be isolated from 0.3 mm tissue cores taken from tumor 
fields of FFPE tissue blocks. We used 3 tissue cores from 4 colon tumor / normal 
pairs, respectively for the classic and automated isolation methods as described 
in the material and methods. Final DNA was collected in 100 µl PK1 for the classic 
and 100 elution buffer for the automated method. To check for the quality of the 
material we performed the 8 hydrolysis probes assays with 2 µl of a 1:5 diluted 
stock of both eluates (Supplementary table 1). All 64 data-points were plotted in 
a scatterplot (Figure 1A). The mean Cq of the “Classic samples was 31.45 with 
a standard deviation of 1.55. The automated method had a mean Cq of 32.23 
with a standard deviation of 1.96 demonstrating that Cq values obtained with 
the Classic method are in the same range as the Cq values obtained with the 
automated method.
Figure 1. Scatter plots of hydrolysis 
probes assays Cq values over 
isolation type. Plot A shows the Cq 
values obtained in DNA isolated from 
tissue cores in equal amounts of DNA 
obtained with the classic and fully 
automated method with 8 different 
hydrolysis probes assays for KRAS 
and BRAF. Plot B shows the Cq 
values obtained with equal amounts 
of micro-dissected DNA in 8 different 
hydrolysis probes assays for KRAS 
and BRAF. Plot C shows the Cq 
values obtained with a BRAFV600E 
Hydrolysis probes assay on samples 
in two different, however comparable 
sets of samples tested in two different 




In our laboratory micro-dissection for tumor cell enrichment, where 8 to 10 
consecutive 10 micron sections are used as starting material, is required in about 
40% of the cases. Deparaffinized and stained tumor containing fields are scraped 
off the different slides and pooled. This process, at about 5 minutes per slide, 
adds up to approximately 1 hour hands-on time. 
We determined the threshold for the minimal input of the automated system 
by micro-dissecting in duplicate 1, 2 and 4 mm² tissue from deparaffinized and 
stained sections of a single 10 micron slide of a colon and a lung specimen. DNA 
was extracted with the automated method and eluted in a final volume of 100µl. 
Two µl of the eluate was used in the KRAS and the BRAF hydrolysis probes 
assay. Mean Cq values of 31.97 +/- 1.6, 31.45 +/- 1.5 and 29.93 +/- 1.3 were 
observed for the 1, 2 and 4 mm² tissue sections, respectively (Supplementary 
table 2). This demonstrates that as little as 1 mm² micro dissected tumor material 
of a single 10 µM slide can produce enough DNA to perform 50 qPCR reactions 
when using the automated extraction method. In the colon cancer specimen a 
KRAS c.34G>A mutation was clearly detectable in the 1, 2 and 4 mm² micro-
dissected tissue sections. Remarkably the wild type allele tended to disappear in 
the 1 mm² .This may possibly be explained by the loss of the wild type allele or 
preferential amplification of the mutant allele. (Figure 2)
Figure 2. Minimal input testing in the fully automated system. Wild type (orange) and 
mutant (blue) amplification curves of 1mm2 (Circle), 2mm2 (Triangle) and 4mm2 (Cross) 
micro-dissected tissue parts originating from one single 10 µM slice of a lung tumor 
harboring a KRAS c.34G>A p.G12S mutation.
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Subsequently, micro-dissection was performed on 14 different tissue type 
specimen to enrich for tumor cells (Supplementary Table 3). Like in routine 
diagnostics, eight sections per specimen were used for the classic isolation with 
micro-dissection. These were compared to two sections per specimen for micro-
dissection with the automated DNA isolation, thus 2x1 mm2 or more tissue was 
available for processing. The classical isolates were eluted in PK1 varying from 
12.5 to 75 µl depending on the amount of tumor material present (Supplementary 
table 3). DNA isolates from the classical method was diluted five times in sterile 
water prior to hydrolysis probes assays while 2 µl of undiluted DNA obtained 
with the automated method was always used. Eight assays detecting KRAS and 
BRAF hotspot mutations were performed and Cq values were compared. The 
mean Cq for the classical method was 32.10 +/- 2.9 and the automated method 
had a mean Cq of 32.18 +/- 1.9. This indicated that although 4 times less tissue 
was used for the automated method similar Cq’s were obtained. (Figure 1B). 
These results demonstrate that the automated method leads to at least the same 
quality DNA and detection rates of mutations as compared to the manual method 
while workload can be reduced and quicker turnover (turnaround) times can be 
achieved. In the classical protocol, micro dissecting ten replicates for each of 14 
samples requires up to 7 hours hands-on time resulting in a total time including 
DNA extraction of about 28 hours before isolated DNA is available for assay 
(Figure 3). With the automated approach, micro dissecting only two replicates for 
each of 14 samples requires up to 2 hours hands-on time resulting in a total time 
including DNA extraction of about only 6 hours before isolated DNA is available 
for assay (Figure 3). 
To determine if the automated approach will have a positive effect on both the 
hands-on time and turnover (turnaround) time we performed the automated 
approach for four consecutive weeks. Although the initial experiments 
demonstrated that micro-dissection on two slides generally yielded sufficient 
DNA for each test, we used 5 slides for micro-dissection in order to always 
guarantee sufficient DNA concentrations, accounting for very small tumors and/
or much degraded tissues. Using 5 slides for microdissection still reduces the 
workload by half when compared to the classical method. To demonstrate that 
the hydrolysis probe assays perform equally well with DNA from both methods 
we compared the overall results from the four week interval with a previous four 
week interval in which samples were isolated with the classical method. In the 
first time interval, DNA from 66 samples was isolated using the classical method 
and Cq values for the KRAS and V600E assays were measured. In the second 
time interval, the identical assay was performed on 70 independent samples 
for which DNA was isolated using the fully automated method. In this way we 
compared a consecutive, representable series of DNA from tumor tissue cores 
or microdissected tumors from different tissue types (Supplementary Table 4). 
For the BRAF V600E assay the results are shown in figure 1C. The Mean Cq 
for the classical method was 29.20 +/- 3.14 and 30.03+/-2.88 for the automated 
method. This indicated that both methods compared well despite the different 
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amount of input DNA. (Figure 1C). For the 7 KRAS assays comparable results 
were obtained (Supplementary Figure 1). 
Discussion 
We demonstrated that a fully automated DNA isolation method is an excellent 
tool to obtain hands-on time reduction and lower turnover (turnaround) times in 
the daily practice of molecular tumor diagnostics. In an ideal situation the use of 
the fully automated system allowed for molecular test results to be delivered to 
the clinic about 24 hours earlier than when the classical DNA isolation method 
was used. However, it still remains to be seen if this gain in time can also be 
achieved in daily practice. (Figure 3)
Figure 3. Laboratory implications for the fully automated method. Time evaluation of 
hands-on (red bar) and hands-off (green bar) workflow from tissue section to first molecular 
results. In the classical approach we start on Monday morning with the micro-dissection of 
10 slides per sample request. One or two technicians work through this process until about 
the middle of the afternoon. In contrast, with the automated approach, micro-dissection is 
performed on only five tissue sections, and the work is finished around noon. Consequently, 
50% of the hands-on time is saved. With the classical approach, on Monday afternoon the 
whole tissue sections or tissue cores are prepared and deparaffinized and an overnight 
Proteinase-K step is initiated. In the automated approach, the technician(s) finish the 
micro-dissection and start the DNA isolation around noon on Monday. At this point they 
can walk away from the system. The entire extraction is finished on the same day. On the 
following day (Tuesday) hours of hands-on time can be saved because the technician can 
immediately start with the qPCR processes instead of finishing the DNA isolation. This 
then results in the transfer of the results to the clinicians on Tuesday afternoon instead 
of Wednesday morning. In the near future it might be even possible to start the qPCR 
reaction on Monday afternoon which makes it possible to have the results reported to 
the clinic on Tuesday before noon. These results show that hands-on time, from tissue 
slide to first molecular results, can be reduced by approximately 50% . In addition, it is 
likely that the turnaround time can be further reduced to less than 24 hours in the near 
future. To make this process transparent to a broader public the department of Pathology 
made a video presentation of this process which can be viewed on http://www.scivee.tv/
node/39348 (accessed February 24, 2012).
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The isolated DNA is suitable for mutation detection by high throughput 
processes like routine hydrolysis probes assays. We demonstrated that in small 
deparaffinized tissue cores DNA of at least the same quality and quantity as 
with the classic method can be isolated. In many cases where micro-dissection 
is required the automated system provides significant added value in the whole 
process. Although deparaffinization and staining has already been performed 
before actual micro-dissection takes place at least 50% hands-on time can be 
saved by the fact that only 2mm2 of material from a single 10µm slide is actually 
required for good quality DNA. Further, the consumption of rare and precious 
patient material is dramatically reduced. Thus, the automated extraction method 
can also decreases the burden on a patient by allowing for the isolation of DNA 
from minimal biopsies or other very small tissue fragments instead of larger tissue 
resections obtained by invasive surgery. DNA isolated with the automated system 
using nano-bead technology promises to be of sufficient quality and quantity for 
use in additional applications. It also potentially avoids pre-amplification protocols 
like whole genome amplification which again saves hands-on time, turnover 
(turnaround) time and costs. 
The first results of using DNA obtained from the fully automated system in Sanger 
sequencing demonstrate that the overall quality of the sequences is higher than 
in the classical process (assessed by internal quality score; data not shown). 
Consequently, extra DNA treatment with whole genome amplification procedures 
can probably become obsolete for this application. Further validation of the 
automated extraction method should be performed for other types of assays such 
as Microsatellite Instability testing, clonality typing, MLPA, Maldi-tof, SNP arrays 
and high throughput and deep sequencing. 
We conclude that the fully-automated IVD extraction system delivers sufficient 
and high quality DNA from precious FFPE tissue cores and micro-dissected 
tissue material. It significantly reduces the amount of starting tissue and labor 
and turnaround time. The automated and standardized extraction procedure can 
contribute to less operator-to-operator variability and reduces contamination risk 
between samples. In addition, the flexibility of the automated system including 
the ability to process between 1 and 48 samples per run and to select different 
protocols for both DNA and RNA while using the same reagents and protocol 
makes it very amenable for current and future high-throughput molecular 
laboratories.
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Multiplex Ligation-Dependent Probe Amplification (MLPA) is a new assay for the 
detection of multiple chromosomal deletions in tumor tissue in a single experiment. 
Since genotyping of gliomas with oligodendroglial features by the detection of 
1p/19q chromosomal deletions became essential for treatment decisions, we 
developed and validated an MLPA- based assay to determine these losses in 
formalin fixed and paraffin embedded oligodendroglial tumors (OG). Nineteen 
OG, and 10 control samples were analyzed by MLPA and the results were 
correlated with those obtained by fluorescent in situ hybridization (FISH). The 
MLPA results were reproducible in all samples in which repeated experiments 
were performed. In 18 of 19 OG MLPA and FISH were concordant for presence 
or absence of 1p deletion. In 3 OG, MLPA detected a 19q deletion not shown by 
FISH. For the other 15 OG MLPA and FISH were concordant. In one sample with 
50-75% of tumor, MLPA failed to detect the 1p/19q deletions revealed by FISH 
(though with borderline values of significance). We conclude that MLPA is a valid 
and reproducible method for the detection of 1p/19q chromosomal deletions in 
OG stored on formalin fixed, paraffin embedded tissue. 
Introduction
Gliomas are a group of primary brain tumors presumably originating from the 
astrocytic and/or oligodendroglial cell lineage. An oligodendroglial morphology in 
gliomas is associated with chemosensitivity and a relatively favorable prognosis, 
as well as deletions of the short arm of chromosome 1 and the long arm of 
chromosome 19 (1,2,8,10). More specific, chemosensitvity and 1p/19q deletions 
are most frequent in oligodendrogliomas, less frequent in gliomas showing 
both oligodendroglial and astrocytic phenotypes (oligo-astrocytomas) and least 
frequent in astrocytomas (8,10,13). The determination of 1p/19q deletions in 
gliomas is likely to result in a more reproducible and biologically and clinically 
more meaningful sub-classification of gliomas than the current classification, 
which is, to a large degree, based on subjective morphological criteria. Since 
the presence of 1p and/or 19q physical deletions in gliomas appears to be a 
better predictor for chemosensitivity and prognosis than morphology alone, there 
is growing need for a practical assay to determine these deletions in the routine 
clinical practice (3,11,13).
So far, a variety of methods for detection of 1p and 19q loss in gliomas have 
been used, like Fluorescent In Situ Hybridization (FISH) (10,12), detection of loss 
of heterozygosity (LOH) by microsatellite repeat analysis (5), and quantitative 
microsatellite analysis by real-time PCR (QUMA) (6).
Multiplex ligation dependent probe amplification (MLPA) is a recently developed 
technique for the relative quantification of DNA sequences that can detect 
chromosomal deletions or amplifications (4,7,9,14). The principle of MLPA is that 
two DNA oligonucleotides are directly adjacent hybridized to their complementary 
target sequences on the template DNA, followed by ligation of these two 
oligonucleotides. One oligonucleotide contains a target specific part with an M13 
forward tail, the second probe contains a target specific part linked to a variable 
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length stuffer sequence and an M13 reversed tail. The two oligonucleotides can 
only be ligated together if both target specific parts are hybridized adjacently 
to their DNA template. PCR is then performed making use of the M13 primer 
sequences on the ligation product. PCR can only start after successful adjacent 
hybridization and ligation of both oligonucleotides, which ensures specificity 
of probe amplification. MLPA is thus characterized by PCR performed on the 
ligated two oligonucleotides (forming the probe) and not on the template DNA. 
The amount of ligated probes is related to the number of specific primer binding 
sites, making this method suitable for the detection of chromosomal deletions or 
amplifications. 
MLPA has several advantages over currently used techniques: 1) up to 40 
genomic loci can be analyzed in one reaction (9), 2) paired non-neoplastic tissue 
from the same patient is not needed and there are no non-informative loci, 3) 
requires only small amounts of DNA, (20ng is sufficient for 1 reaction in which 40 
loci can be tested) (9), 4) is probably less sensitive to DNA degradation because 
probe target sequences are small (50-70bp) (9).
To the best of our knowledge, there are no reports about the feasibility of MLPA for 
the detection of 1p/19q deletions in oligodendroglial tumors (OG). The objective 
of the present study was to develop an MLPA based assay for the detection of 
1p/19q chromosomal deletions in formalin fixed, paraffin embedded OG and to 
test the validity and reproducibility of this assay. 
Materials and methods
Patients
Nineteen OG from 19 patients were analyzed. From all tumors FISH data were 
available. The tissue was obtained by stereo tactic biopsy or surgical excision and 
routinely formalin fixed (around 16 hours) and paraffin embedded (4-11 years). 
All tumors received a histological diagnosis according to the WHO criteria (JMK) 
(Table 2). Tumor percentages in isolated tissue were above 75% in 15 tumors, 50-
75% in 3 tumors and around 50% in one tumor. Control brain tissue was obtained 
from microscopically unaffected brain areas of 3 of the above patients with an 
OG, 6 autopsy brains and 1 lymph node (5 of these autopsy brains were without 
abnormalities and 1 brain was from a patient with hereditary cerebral hemorrhage 
with amyloidosis, Dutch type). Autopsy brains were fixed for 24 hours (3X), 3 
days (1X) or unknown (2X). 
DNA isolation
Guided by the HE section, tumor or non-neoplastic tissue was punched from the 
paraffin embedded tissue blocks with a tissue array needle (Beecher Instruments, 
Silver Spring, MD) and deparaffinized by 2x 15 minutes incubation in xylol, 
followed by 2x 15 minutes incubation in ethanol. Tissue cores were resuspended 
in 128 mL of PK-1 lysis buffer [50 mM KCl, 10 mM Tris (pH 8.3), 2.5 mM MgCl2, 
0.45% NP40, 0.45% Tween 20, 0.1 mg/mL gelatine] containing 5% Chelex beads 
(Biorad, Herculaes, USA) and 100 mg of proteinase K. The suspension was 
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FLJ10782-D01-247-M 01p36.33 01-002.45 16 247
FISH-probe D1S32 01p36    
TP73-D01-256-M 01p36 01-003.6 17 256
TNFRSF1B-D01-166-M 01p36.3 01-012.1 7 166
MUTYH-D02-310-M 01p34.3-1p32.1 01-044.8 23 310
BCAR3-D01-418-M 01p13.2 01-093.4 35 418
F3-D01-139-M 01p22-p21 01-094.2 2 139
BCAS2-D01-400-M 01p13.3 01-114.0 33 400
FISH-probe PUC 1.77 01cen    
TANK-D01x-220-M 02q24 02-160.6 13 220
CHL1-D01-265-M 03p26 03-000.3 18 265
MLH1-D13-355-M 03p21.3 03-036.3 28 355
MLH1-D17-436-M 03p21.3 03-036.3 37 436
APC-D09B-283-M 05q21-q22 05-112.6 20 283
APC-D01-175-M 05q21-q22 05-112.6 8 175
IL4-D01-154-M 05q31.1 05-132.5 5 154
IL12B-D01-382-M 05q31.1-q33.1 05-159.3 31 382
RAD54B-D01-292-M 08q21.3-q22 08-095.3 21 292
RB1-D03-193-M 13q14.3 13-043.0 10 193
RB1-D17B-160-M 13q14.3 13-043.0 6 160
FISH-Probe BAC2310A1 19p13    
BAX-D01-301-M 19q13.3 19-049.8 22 301
BAX-D02-211-M 19q13.3 19-049.8 12 211
FISH-probe BAC127F23 19q13    
KLK3-D02-391-M 19q13 19-051.7 32 391
LOC125905-D01-450-M 19q13.43 19-059.4 38 450
Table 1. MLPA and FISH probes included in the analysis.
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incubated for 12 h at 56 °C, 10 min at 100 °C and after 10 minutes centrifugation 
at 13.000g, the DNA containing supernatant was collected.
DNA quality
DNA concentration was measured with PICO green (Molecular Probes Europe 
BV, Leiden, the Netherlands) according to the manufacturers protocol. DNA 
concentration ranged from 5.2 – 154ng/ul, median 9.9 ng/ul. For testing tumor DNA 
quality, a PCR reaction was performed on P53 exon 8 generating a 239-basepair 
product in controls. The primer sequences were: ex8-forward, GTA GGA CCT 
GAT TTC CTT ACT GCC TCT TGC, ex8-reversed ATA ACT GCA CCC TTG GTC 
TCC TCC ACC GC. Each reaction was performed in 25 mL using AmpliTaq Gold 
™ at 94 °C for 10 minutes initial denaturation followed by 35 cycles of 94 °C for 
45 s, 57°C for 30 s and 72°C for 1 min. Products were analyzed on a 2% agarose 
gel to confirm size and quantity (data not shown).
MLPA detection
MLPA has previously been described (9). In brief, MLPA is based on the ligation 
of two DNA oligonucleotides that hybridize adjacently to DNA target sequence. 
The first oligonucleotide was synthesized with an on average 26bp (min: 21bp, 
max: 39bp) target specific part and a universal M13-forward tail. The second 
oligonucleotide was an M13-derived single stranded DNA containing an, on 
average, 42bp (min: 31bp, max: 50bp) target specific part, a stuffer sequence 
of variable length (130-480 base pairs) and an M13-reversed tail. Thus, a probe 
consists of two oligonucleotides of which the target specific parts hybridize 
adjacently and ligate. The M13 forward and reversed tails attached to all probes 
and the different length of each probe made it possible to perform a single primer 
multiplex PCR. 
Twenty-two probes of the 40 probes in the kit were included for analysis and 
selected on the basis of localization on 1p or 19q (focus probes), likelihood to be 
unaltered in OG (1) (reference probes) and performance (Table 1). The MLPA kit 
was assembled by MRC-Holland (Amsterdam, the Netherlands). Details of MLPA 
and probes can be found at http://www.mlpa.com. 
After denaturing 15-250ng DNA for 5 minutes at 95°C, the probe mix, containing 
all probe sets, was added. After overnight hybridization at 60°C the hybridized 
probes were ligated for 15 minutes at 54°C with a DNA-ligase. An aliquot was 
taken out of the ligation mix and the ligated products were amplified in a multiplex 
PCR with forward and reverse M13 primers for 20 sec at 95°C, 30 seconds at 
60°C and 60 seconds at 72°C for 33 cycles in an Applied Biosystems® 9700 PCR 
machine. After PCR 3 mL of the PCR products were mixed with 1 mL 500 TAMRA 
(Applied Biosystems ®) internal size marker and 20mL deionised formamide and 
injected for 5 seconds in an ABI310® capillary filled with POP5 polymer. After a 
30 minutes run the data were collected and analyzed with Genescan analysis 
and Genotyper software (Applied Biosystems®) (Figure 1). A Genotyper output 
file was generated combining probe set number, size and peak heights. This 
table was exported to a database where probe annotation is added to the data 
table. Subsequently normalization and diagnosis of the profiles were performed. 
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Figure 1. Examples of ABI electrophoresis signals in MLPA. A: Two control DNA samples 
showing reproducibility of MLPA patterns of all 40 probes in the kit, of which 22 were 
selected for analysis. Peakheight differences for the different loci are due to probe length 
(smaller probes give higher peaks/signals due to more efficient PCR) and differences in 
binding kinetics for each oligonucleotide. Differences in absolute peakheights between 
samples are probably due to differences in DNA concentration. B: Fragment of an MLPA 
pattern showing decreased peak heights of probes on 1p and 19q in an oligodendroglioma, 
indicating chromosomal loss. 
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Data analysis for MLPA
Normalization
Because MLPA traces analyzed with Genescan and Genotyper are not calibrated, 
raw data files had to be normalized. Peak heights were dependent on sample 
quality, DNA concentration, hybridisation parameters and instrument settings. 
Also peaks from different probe sets differed in magnitude in a systematic way 
(Figure 1). To calibrate the data, we used the following algorithm:
1. Distinguish focus probes (seven and four loci on chromosome 1p and 19q 
respectively) and reference probes (11 loci usually unaltered in OG).
2. Select the reference probes from the control (non-tumour) samples. Perform 
steps 3 to 5 with this subset of data.
3. Within each sample divide all peak heights by the median peak height of the 
concerning sample. This is to correct for the sample-to-sample variation. 
4. Within each probe, divide all peak heights by the median peak height of 
the concerning probe. This is to correct for systematic differences between 
probes. The result of 3 and 4 we call normalized peak heights.
5. Determine which (reference) probes are most stable. Subtract 1 from each 
normalized peak height and take the absolute value. Compute the median of 
these numbers for each probe. This is the median of the absolute deviations: 
MAD. 
6. Select the 5 reference probes with the lowest MAD. These 5 reference 
probes are named calibration probes and are used to normalize the complete 
experiment as described in step 7 and 8.
7. Within each sample (OG and normal control samples) divide all peak heights 
(focus and all reference probes) by the median peak height of the five 
calibration probes of the concerning sample. This is to correct for the sample-
to-sample variation.
8. Within each probe (focus and reference probes), take the median peak height 
of the control samples. Then, within each probe (focus and reference probes) 
divide all peak heights (OG and normal control samples) by the median peak 
height of the concerning probe. This is to correct for systematic differences 
between probes.
Computing was initially performed in Matlab (The Mathworks inc., Natick, MA, 
USA). A Windows analysis interface was constructed using Delphi. The application 
is available on request (J.Oosting@lumc.nl).
Data visualization and interpretation.
Each experiment was normalized and analyzed separately. Heatmaps were 
generated for each experiment using Matlab (Figure 2) and scatter plots for 
each individual Tumor and Normal were generated in Matlab (Figure 3) and 
anonymized. Two authors (SvD an RN) independently decided if a scatter plot 
showed a deletion or not. The principle decision rule for a deletion was that for 1p 
at least 4 probes and for 19q at least 2 focus probes had normalized peak heights 
at least 0.25 below the median normalized peak height of the reference probes. 
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Figure 2. Heatmap representing an overview of a complete experiment. On the Y-axis 
samples are shown. The X-axis shows the different probes in chromosomal order. R 
indicates the 5 probes with least variance the Normal samples, and these were used for 
normalization. Chromosomal loss (yellow) or gain (blue) is shown.
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FISH
The 1p and 19q status of all 19 OG was determined with fluorescence in situ 
hybridization on paraffin embedded, archival material using locus specific probes 
as earlier described (13). The cut off value to decide whether a 1p or 19q deletion 
was present or absent was 0.8.
Results
DNA quality was checked by a standard 239bp PCR, which was negative in 
3 tumor and 2 control samples and weak in 4 tumor and 3 control samples. 
However, MLPA showed reproducible peak heights in these samples (Table 2). 
Electrophoresis was repeated once or twice in each experiment and gave highly 
reproducible results (Figure 2 and 3). 
In 15 OG and 5 controls 2 to 4 experiments were performed. For all samples the 
different experiments showed consistent results, with little variation in the amount 
of focus probes with a normalized peak height of at least 0.25 below the median 
of the reference probes (Table 2). 
In 18/19 OG, results of MLPA and FISH were concordant for presence or absence 
of a 1p deletion. In 15/19 OG, results of MLPA and FISH were concordant for a 
19q deletion. In 3 OG, MLPA detected a 19q deletion, which was not shown by 
Figure 3. Representative scatterplots of normalized peakheights. Each plot represents 
one sample from one experiment with electroforesis in duplicate or triplicate. On the left 
in white 1p, on the right in white 19q, in grey the reference probes. A: Non-neoplastic 
brain tissue. B: Oligodendroglioma with FISH 0.99 for 1p and FISH 0.95 for 19q. C: 
Oligodendroglioma with FISH 0.59 for 1p and FISH 0.57 for 19q. D: Oligodendroglioma 
with FISH 0.54 for 1p and FISH 0.58 for 19q.
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        MLPA/FISH concordant
DNA-





109N N pos 1 ret (0) ret (0)     
111N N pos 2 ret (0-0) ret (0-0)     
113N N pos 1 ret (0) ret (0)     
114N N pos 1 ret (0) ret (0)     
115N N neg 1 ret (0) ret (0)     
116N N weak 1 ret (0) ret (0)     
122N N pos 2 ret (0-0) ret (0-0)     
13N N weak 4 ret (1-0-0-0) ret (0-0-0-0)     
15N N neg 3 ret (0-0-2) ret (0-1-0)     
18N N weak 4 ret (1-0-0-0) ret (0-0-0-0)     
1T AO pos 3 del (7-7-7) del (4-4-4) 0.54 0.58 + +
2T OA neg 1 ret (0) ret (0) 1 1.05 + +
3T AO pos 2 del (7-7) del (4-4) 0.66 0.78 + +
4T AO pos 2 del (7-7) del (3-3) 0.67 0.75 + +
5T AO neg 2 del (4-5) del (2-2) 0.46 0.85 + -
6T AO pos 2 del (7-7) del (4-3) 0,68 0,60 + +
7T AO pos 2 ret (0-0) ret (0-0) 0.99 0.95 + +
8T AO weak 1 ret (1) ret (0) 1.06 0.89 + +
9T AO pos 3 del (7-7-7) del (4-4-4) 0.59 0.57 + +
10T AO pos 2 ret (0-0) ret (0-1) 1.06 1.04 + +
11T AO pos 4 del (5-7-7-7) del (4-4-4-4) 0.73 0.68 + +
12T AO pos 2 del (7-7) del (4-4) 0.67 0.64 + +
13T AO weak 3 del (6-7-6) del (3-4-4) 0.74 0.85 + -
14T OA neg 3 ret (0-0-3) ret (0-2-0) 1.02 1.06 + +
15T AOA weak 1 ret (1) ret (0) 0.95 0.97 + +
16T AO pos 1 del (4) del (3) 0.42 1.13 + -
17T AO pos 2 del (4-7) del (2-3) 0.66 0.59 + +
18T O pos 3 ret (0-0-0) ret (0-0-0) 0.73 0.79 - -
19T AO pos 2 del (7-7) del (4-4) 0.66 0.57 + +
Table 2. MLPA and FISH results. PCR= standard polymerase chain reaction to test DNA 
quality, see “Methods”. Exp=number of MLPA experiments. N=non-neoplastic brain tis-
sue. O=oligodendroglioma, AO=anaplastic oligodendroglioma. OA=oligoastrocytoma. 
AOA=anaplastic oligoastrocytoma. ret/del= retention/deletion of chromosome1p/19q. The 
principle decision rule for a deletion was that for 1p at least 4 (out of 7) focus probes and 
for 19q at least 2 (out of 4) probes had normalized peak heights at least 0.25 below the 
median normalized peak height of the reference probes. Numbers between brackets state 
for each MLPA experiment the number of focus probes with a normalized peak height of at 
least 0.25 below the median normalized peak height of the reference probes.
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FISH. These 3 OG carried a 1p deletion according to both FISH and MLPA. In 
two of these samples, FISH results were close to the cut off value of 0.8. Only 
one sample showed inconsistent MLPA- and FISH results for both 1p and 19q 
status. This sample contained 50-75% tumor cells and the FISH results for 19q 
were close to the cut off value (Table 2, tumor 18T). None of the controls showed 
1p/19q deletions. The amount of focus probes with a normalized peak height 
of at least 0.25 below the median of the reference probes is shown for each 
DNA sample and each experiment in Table 2. If not all focus probes in tumor 
samples with a deletion showed a normalized peak height of at least 0.25 below 
the median of the reference probes there was often a trend towards this value. 
The study was not designed for, and the data did not permit, the identification of 
breaking points. 
The 3 tumor DNA’s with negative control PCR all showed reproducible MLPA 
results consistent with FISH (Table 2).
Discussion
We showed that MLPA is a valid, reproducible, fast and simple method for the 
detection of physical 1p/19q deletions in DNA isolated from formalin fixed, paraffin 
embedded brain tissue. To the best of our knowledge, the use of MLPA for the 
detection of 1p/19q chromosomal loss in OG has not been described before. 
MLPA is less limited by poor DNA integrity than conventional PCR because 
the probe target sequences (the combined binding specific domains of the 2 
ligated oligonucleotides) are only 50-70bp (9). In the present study the use of 
formalin fixed, paraffin embedded material, even when stored for over 10 years 
(2 samples 11 years, 1 sample 10 years) and with only little amounts of DNA (as 
little as 15ng in the present series) yielded satisfactory results. Moreover, MLPA 
appeared to be more sensitive than conventional PCR. MLPA gave reproducible 
peak heights in 2 control- and 3 tumor DNA’s with negative conventional PCR, 
normally generating a 239bp product. 
MLPA is probably less sensitive to variations in DNA quality between samples 
than other techniques because, from the first round of amplification, ligated 
probes are amplified and not template DNA. Furthermore, the variable length of 
stuffer sequences in one of the probes permits the performance of multiplex PCR 
(40, and potentially more, reactions in one well), enabling the analysis of a large 
number of loci in a highly efficient way. 
As compared to FISH, MLPA is performed in shorter time, is less elaborate 
and less dependent on individual interpretation. In addition, only one marker 
per experiment can be assessed using FISH. Tracing of chromosomal losses 
in individual tumor cells, for instance in infiltration margins of gliomas, is 
possible using FISH, but in the majority of studies FISH is used for detection of 
chromosomal aberrations in fields of tumor cells, not individual cells. For MLPA 
probably the majority of tissue needs to consist of tumor cells. In the present 
study we analyzed one tumor (tumor 18, table 2) with 50-75% of preexistent cells 
and were not able to detect a 1p or 19q deletion shown by FISH, although with 
borderline values of significance. 
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MLPA certainly has advantages over QUMA or LOH detection by microsatellite 
analysis. From the first round of amplification, PCR is performed on ligated 
probes instead of template DNA making PCR conditions more comparable 
between samples. Furthermore, MLPA is likely to work better on paraffin 
embedded material because probe target sequence (50-70bp) is smaller than 
the product lengths used in QUMA (in which expected product lengths length 
varied between 81-93bp and 145-157bp among the different probes) (6) or LOH 
(in which expected product lengths length varied between 69-110bp and 130-
185bp among the different probes) (5). In addition, extended multiplexing with 
40, and potentially more, loci in on reaction is possible, which is difficult with LOH 
detection by standard microsatellite markers or QUMA. To test the same amount 
of loci in conventional LOH or QUMA analysis is more elaborate and takes much 
more DNA. For QUMA it was reported that at least 15ng DNA per locus was 
required (6). In the present study, only 15ng of DNA was enough to determine 
the relative amount of DNA at all 22, and potentially more, loci. An additional 
major advantage of MPLA over LOH detection with microsatellite markers is that 
patient-matched normal DNA is not necessary. Any normal DNA can be used as 
a control. This is especially relevant for brain tumor biopsies and excisions in 
which ‘normal’ surrounding tissue is either not available or often contains variable 
amounts of infiltrating tumor cells.
We tested and validated a MLPA based assay for the detection of 1p/19q deletions 
in formalin fixed, paraffin embedded brain tissue. MLPA enables the introduction 
of many more probes in one reaction than presented in the present paper, 
potentially enabling the routine analysis of all clinically relevant or scientifically 
interesting chromosomal deletions and amplifications of oligodendrogliomas, 
oligo-astrocytomas and astrocytomas in one assay. It is likely that this information 
will improve classification of these tumors, enable a more reliable estimation on 
prognosis and guide therapeutic decisions. The present results suggest that 
MLPA on paraffin embedded tissue may also be used for clinically or scientifically 
relevant chromosomal deletions or amplifications in other malignancies like HER-
2/neu amplification in breast cancer.
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Multiplex Ligation-Dependent Probe Amplification (MLPA) is an application that 
can be used for the detection of multiple chromosomal aberrations in a single 
experiment. In one reaction, up to 50 different genomic sequences can be 
analysed. For a reliable work-flow, tools are needed for administrative support, 
data management, normalisation, visualisation, reporting and interpretation. 
Results
Here, we developed a data management system, MLPAInter for MLPA 
interpretation, that is windows executable and has a stand-alone database for 
monitoring and interpreting the MLPA data stream that is generated from the 
experimental setup to analysis, quality control and visualisation. A statistical 
approach is applied for the normalisation and analysis of large series of MLPA 
traces, making use of multiple control samples and internal controls. 
Conclusions
MLPAinter visualises MLPA data in plots with information about sample replicates, 
normalisation settings, and sample characteristics. This integrated approach 
helps in the automated handling of large series of MLPA data and guarantees 
a quick and streamlined dataflow from the beginning of an experiment to an 
authorised report. 
BACKGROUND
In medical research, knowledge of chromosomal deletions or amplifications is 
of great importance. For example, it can help us better understand the genetic 
causes of certain diseases and as a consequence, improve the treatment 
and prognosis of individual patients. Classic techniques for the detection of 
chromosomal abnormalities include karyotyping, Southern blotting, Fluorescent 
In Situ Hybridisation (FISH), CA-repeat analysis and quantitative micro satellite 
analysis by real-time PCR [1-4]. In recent years, high-throughput methods based 
on BAC arrays, SNP arrays and related techniques have gained prominence [5,6]. 
Although these are excellent tools for whole genome analysis, these techniques 
are laborious, time-consuming, difficult to implement, expensive and generate 
large data sets. The management and interpretation of such voluminous data is 
not a light task. Multiplex Ligation-dependent Probe Amplification (MLPA) [7] has 
been introduced as a relatively cheap and fast method to perform quantitative 
chromosomal analysis of up to about 50 genomic DNA or RNA sequences, which 
is able to distinguish sequences differing in only one nucleotide. This technique fills 
the gap between the methods that investigate a single locus and the techniques 
that interrogate thousands of loci. 
MLPA is a quick and cost effective approach to testing for the presence of gene 
deletions or obtaining tumour profiles on multiple loci in a single tube, which 
can easily be applied in molecular pathology. Furthermore, MLPA only requires 
small amounts of DNA. Moreover, DNA obtained from formalin fixed paraffin 
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embedded material can be used. Currently, MLPA is used for the validation of 
array-based comparative genomic hybridisation (array-CGH) and SNP arrays. 
[7-12]. Other applications for MLPA include methylation status determination, 
copy number analysis in segmentally duplicated regions, expression profiling, 
and transgene genotyping [13]. The principle of MLPA is that for each locus, 
two DNA oligonucleotides (probes) must hybridise to their complementary target 
sequences on the template DNA for ligation to occur. Subsequently a PCR 
reaction is performed on the ligated probes. After PCR, an aliquot of the PCR 
product is combined with an internal size marker and deionised formamide. The 
sample is then injected into a capillary of an automated sequencer, where after 
a 30 minutes run, the data are subsequently collected for further analysis. Since, 
the amount of ligated probes is dependent on the number of specific primer 
binding sites, this method is suitable for the detection of chromosomal deletions 
or amplifications [7]
The analysis, visualisation and data management of hundreds of samples with 
many different probes per reaction can be cumbersome. Like in many modern 
techniques, the results of an MLPA analysis are delivered as lists of values that can 
be easily imported into spreadsheet applications. Large collections of individual 
spreadsheets are not the best way to collect and analyse data, especially in an 
environment where a controlled work flow has to be guaranteed. A database 
system offers advantages such as the tracking of material used in the tests and 
consistency in the handling of test results. Some of the information that needs 
to be managed includes: the origin of normal and test samples, the experimental 
setup, the identity of the probes, and the quality settings. Normalisation has to 
be performed within and between samples and results have to be visualised 
and stored. Sophisticated tools are needed to facilitate the reliable use of MLPA 
[7,9,14-16]. In this paper, we present a statistical technique for the normalisation 
of MLPA data and the software component that we have developed to make 
MLPA a simple, effective, and attractive tool. Here we describe MLPAinter, for 
MLPA interpretation, a system that stores results, instrument settings and sample 
descriptions in a Microsoft Access database. A special front-end, written in the 
Borland Delphi language, allows the user to interrogate the database, normalise 
data and visualise results as heat maps and specialised plots. 
IMPLEMENTATION
MLPA probe kits are obtained from MRC-Holland (Amsterdam, The Netherlands). 
All assays are performed according to the manufacturers’ protocols on an ABI 
DNA sequencer (Applied Bio Systems, Foster City, CA, USA). MLPAinter was 
constructed using Delphi 2009 (Embarcadero, San Francisco, CA, USA) for the 
GUI, and Microsoft Office Access 2003 (Microsoft, Seattle, WA, USA) for the 
standalone database. The runtime requirements for the application are Windows 
XP or newer. Statistics used in MLPAinter as described below, were validated in 
a series of oligodendroglial tumours as previously described [9]. The source code 
and a step by step protocol to use MLPAinter together with showcase sample files 





MLPAinter can not handle the raw electrophoresis signal and therefore requires 
that the MLPA amplification product peaks have already been linked to the 
corresponding MLPA probes of the used MLPA kit. After electrophoresis, all 
MLPA sample trace files should be pre-processed in standard software for basic 
analysis of MLPA traces. Subsequently, the report files can be imported. Here we 
used GeneMapper (Applied Bio Systems, Foster City, CA, USA) for MLPAinter, 
but the system can also import data from the combination Genescan Analysis and 
Genotyper software (Applied Bio Systems, Foster City, CA, USA). Adaptations to 
other software programs like Genemarker (Softgenetics, State College, PA, USA) 
should be straightforward. A step-by-step vignette for Genemapper settings can 
be found at http://code.google.com/p/mlpainter/. Briefly, the product lengths of 
the ligated probes are defined with an internal size standard. The peak height 
and area are calculated for every peak present in the trace. Any undefined peaks 
are discarded from further analysis. Data tables are then automatically generated 
with length, height and area of all recognised peaks. These tables are exported 
from the Genemapper software package and imported into MLPAinter for specific 
analysis of the raw data. Protocols for linking output files from other software 
packages are planned for future versions. 
Data management
Here, we developed a relational database using Microsoft Access to manage all 
pertinent information for MLPA experiments and created a front end with Borland 
Delphi to guide laboratory workflow and data analysis. Characteristics such as 
the sample number and status, e.g., tumour or normal, DNA concentration and, if 
available, tumour percentages that are relevant for the performance of the MLPA 
should be stored in a database. Annotation information like the chromosomal 
position and gene names of the different probes in a kit should be available for 
the interpretation of the results in output tables, heat maps, and plots. To assist 
the laboratory work-flow, electronic and paper sample sheets can be prepared for 
the automated sequencer. The raw data of the sequencing reports are imported 
into the database for subsequent quality control steps and analysis. 
The relational database contains three hierarchies which are interconnected. 
The hierarchies are MLPA kits and probes, electrophoresis results, and analyses. 
In the database tables, next to the specific Kit information, you can find gene 
and probe names, as well as the physical and cytogenetic location of the 
probes. All probes in a particular kit are numbered from 1, for the probe with the 
smallest product size to n, for the probe with the largest product size. Every kit 
contains a number of probes that can be used for a quality check of the trace. 
The corresponding products are named based on their size in base pairs. The 
different kits as defined by MRC-Holland, can be imported from www.mlpa.com.
Both the MLPA run and analysis hierarchy use the samples table. This table 
contains clinical information like the origin of the used DNA, e.g., if the DNA is 
isolated from whole blood, fresh frozen tissue or formalin fixed paraffin embedded 
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tissue. Every sample is labelled with an N for Normal, T for Test or the Tumour 
origin of the tissue. Normal samples are treated differently from test samples in 
the normalisation and analysis steps as described in the normalisation section. 
An electrophoresis run typically consists of a sample plate to be processed by 
the sequencer. The sample, the kit, and a unique name for the plate are recorded 
for each position on the sample plate. Different types of kits can be used within 
one run. From this information a sample sheet or configuration file is created 
for the sequencer. The resulting peak heights and peak areas of an MLPA run 
are imported for all of the probes in a kit and the analysis settings can be set to 
analyse peak heights or peak areas. 
During analysis, specific MLPA runs can be combined from one or more 
electrophoresis runs. A group of reference probes can be copied from 
another analysis with the same kit, and can be adapted to suit the needs of 
the specific analysis. However, to avoid inter experimental differences, values 
from experiments performed at a different time should not be used. Probes can 
also be excluded from the analysis. Successful analysis can be finalised by 
authorising the results. After authorising the analysis, all options are fixed except 
for visualisation and sorting options. 
Quality control
MLPAinter presents three data quality indicators, Q1, Q2 and Q3, (Figure 1A) to 
assist with the decision of whether to include a trace in the analysis. 
The first indicator (Q1) is the ratio between the ligation dependent peak at 94 base 
pairs and the median of the DNA dependent 64, 70, 76 and 82 peaks (Figure 2). 
Van Dijk et al. [10] state that this ratio should be greater than 5 to obtain good and 
reproducible results. Nonetheless, we have observed that in some cases, lower 
ratios can also give reliable peak patterns (Figure 2).
The second quality indicator (Q2) is the median peak height of the probe signals 
present in the kit. If the median of the first 20 ligated probe peak heights is below 
450 relative fluorescent units (RFU), the trace quality is considered low. Moreover, 
because of the limits in the detection optics of the instrument, a median peak 
height over 4000 RFU is indicative that the trace quality is low (Figure 2) [14].
For the last indicator (Q3) all analysis peaks are split in 2 parts based on sequence 
length. The value is computed as the median signal of the longest probes divided 
by the median signal of the shortest probes. Often the longest probes show lower 
signals, however in high quality traces this indicator is usually over 0.5. 
Other factors that are important for the assessment of quality, which can 
optionally be stored into the database, are the DNA concentration of the sample, 
the tumour percentage of the tumour specimens and the intrinsic DNA quality 
of the sample. The combination of these quality parameters allows the user to 
decide on inclusion or exclusion of a trace from the analysis. 
Normalisation
Raw MLPA results are not calibrated. Peak areas or heights are dependent on 
sample quality, hybridisation parameters and instrument settings. To analyse the 
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Figure 1. MLPAinter for MLPA interpretation. Panel A: Heat map of an authorised series of 
samples after normalisation. The probes are sorted by the name of the gene. The gain and 
loss columns show the total number of probes with gain or loss. Q1-3 show the different 
quality scores calculated from the DNA dependent probes (marked 101-104) and the 
ligation dependent probe (105) and as explained in the text. Dark grey cells: calibration 
probes, the id has a suffix ’c’. Light grey cells: reference probes, the id has a suffix ’r’. 
Yellow cells: probes with loss of one allele (< 0.8). Blue cells: probes with gain of one allele 
(>1.25). Panel B: Sample plot of an individual sample after normalisation. The quality 
indices for each replicate are shown. Replicates are visualised in different colours. Probes 
are sorted by the gene name combined with the chromosomal position. The standard 
scale can be adjusted in case of samples with amplified probes (see panel C).
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MLPA traces, internal and external control loci are used for the normalisation of 
the data. External controls, e.g., normal tissue in tumour analysis, have to be 
present in every experiment for the pattern comparison. Internal controls for the 
calibration of the samples are present in every kit and are supposed to be non-
altered or reference probes in a tumour sample. These reference probes are 
compared to the probes where DNA changes are expected. 
The top trace in Figure 2 shows a normal sample. It is evident that peak heights 
or areas differ between probes; and these differences have to be corrected. Also 
the average peak areas or heights may differ from sample to sample. Therefore, 
sample calibration and probe calibration have to be performed. Consider the data 
as a matrix Y, with columns for the probes and rows for the sample. Then, we need 
to apply normalisation to both rows and columns. Normalisation is implemented 
as division by row parameters ri,i = 1 . . .m and column parameters cj, j = 1 . . . 
n, such that a matrix X = [xij ] results, with xij = y ij /( ri cj). We prefer to work on 
the original scale instead of with logarithms because loss and gain correspond to 
integer ratios (including zero) on the original scale. 
A simple approach would be to take row and column medians for r and c, 
respectively. This could work well if the number of deletions or amplifications is 
relatively small. However, for samples with a large number of deletions (more 
than 50%), the corresponding row median might become a number near zero and 
normalisation by dividing with this small number would give a completely wrong 
result. 
Figure 2. MLPA sample trace files. Overview of 5 different sample traces obtained with 
MLPA kit P105 (Oligodendroglioma-2) showing the necessity of data normalisation. 
Differences in and between samples are hard to distinguish. Quality aspects of every 
trace are visible. Probe lengths in base pairs are shown on the x-axis. Box 1: four no 
template control peaks of 64, 70, 76 and 82 bases, respectively. Box 2: a 94 base pair 
ligation control peak. Box 3 and 4: larger peaks in the first half than in the second half of 
the sample trace. Box 5: peak heights are noted on the y-axis
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To improve normalisation and obtain calibration factors, we use only a subset of 
the samples and probes. Specifically, we use normal samples, and only a subset 
of the probes, where copy number changes are unlikely, even in tumour samples. 
We use the following algorithm: 
1. To correct for the sample-to-sample variation, divide the peak heights or areas 
of all the probes in each sample by their median. This gives provisional row 
parameters, ř for the normal samples, and provisional normalisation of the 
normal samples.
2. To correct for systematic differences between probes, divide the peak heights 
or areas of all the probes within a MLPA run by their median. This results in 
the normalised peak areas or heights, and represents the column parameters 
c for all probes. The average of all probes is now close to 1.
3. Select the probes that have a small probability of change in copy number. 
Call these the reference probes. The remaining probes are called the focus 
probes, since we look for changes in these. The description file for commercial 
kits includes this information, and the program uses these probes by default.
4. Select the part of the data that represents the normal control or non-tumour 
samples and the reference probes.
5. Redo steps 1 and 2 for the subsets of reference samples and reference 
probes.
6. Determine which probes are most stable. Subtract 1 from each normalised 
peak height or area and take the absolute value. Compute for integrated MLPA 
analysis the median of these numbers for each probe. This is the median of 
the absolute deviations: MAD.
7. The reference probes with the lowest MAD are most stable. Select the five 
probes closest to zero. These are the probes that we call the calibration 
probes.
8. Compute the median peak height or area of the 5 calibration probes for each 
sample (normal and test samples or tumours and non-tumours). Divide all 
peak heights or areas as computed in step 2 in each sample by this value. This 
gives the final row parameters r for all samples, and their final normalisation. 
Reference probe selection
As in quantitative RT-PCR, the selection of reference probes is a critical element 
of the analysis [17]. MLPA kits contain about 10 reference probes that are included 
for normalisation purposes because they are not involved in the experimental 
hypothesis/diagnostic question. Alternatively, one can usually find a subset of 
probes in existing kits that are known not to be involved in the hypothesis. The 
procedure selects the most stable probes from the reference probes to calibrate 
the data. The number of calibration probes used (five, in this instance) did not 
significantly influence the results (data not shown). However, the number is 
configurable in the program. If probes show high variability between replicates or 
between normal samples, they should be excluded from the analysis.
MLPAinter for MLPA Interpretation
85 
Visualisation
We have designed a number of visualisations to interpret the results after 
the normalisation and quality control of the data set. The first visualisation is 
a heat map that shows all of the data in an experiment. Deletions and gains 
are colour-coded with configurable thresholds. Probes can be sorted by locus 
names or chromosomal position. The reference and calibration probes are 
clearly differentiated by a grey-shade (Figure 1). Another visualisation shows the 
normalised values of all replicates of one sample in a plot (Figure 1). Technical 
replicates are shown in different colours. On the x-axis, the different probes are 
shown in the selected probe order. The y-axis is on a scale from 0 to 2.5, where 
0 stands for absent probes. Ideally probes at genomic loci with loss of a single 
allele show values around 0.5. Unaltered probes are visualised around 1.0. 
Probes with DNA gains have values around 1.5 or above. In tumour samples 
contaminated with normal DNA these values are usually not that outspoken. The 
researcher should keep this in mind during the interpretation. Information about 
sample characteristics and probes used are also shown in the plots.
Future developments
Currently the system is suited for the analysis, visualisation and data management 
of MLPA. However, all of the information generated during an experiment is still 
not fully integrated in the data analysis. For instance, tumour percentages can be 
stored in the database and will be displayed, but it is up to the user to incorporate 
this information into the interpretation. We plan to include the tumour percentage 
and probably the DNA index for automated identification of the allelic state of the 
chromosomal aberrations in the analysed sample ([18]). 
Another worthwhile improvement would be to remove the dependency on an 
external program to do the peak detection. 
DISCUSSION
MLPA has a variety of applications for the detection of changes in dosage at 
a single locus, e.g., a subtelomeric locus, to those with multiple changes. Up 
to 50 different probes (genomic sequences) can be interrogated in one single 
reaction. Advantages are that only small amounts of DNA are needed and that 
DNA isolated from formalin fixed paraffin embedded material can be used. As 
it stands, currently available software tools for MLPA analysis do not integrate 
data management, normalisation and visualisation, and do not always perform 
adequate data normalisation between and within traces. In these packages, the 
quality aspects of the analysis are not always taken into consideration. Therefore, 
we have developed a method for MLPA data interpreting, MLPAinter, in which 
sample information can be stored, and where the laboratory and analysis 
workflow is assisted. Experiments are prepared by selecting samples and MLPA 
kits. Then sample sheets for automated sequencers are generated, which can 
easily be imported in the sequencer, avoiding manual input and typing errors. 
Analysis tables can then be imported from standard DNA analysis programs. 
Given the sensitivity and reproducibility of this methodology, the requirements 
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for proper internal controls for normalisation have to be stringent [17]. For that 
reason, in each kit, the manufacturer has provided sets of reference probes for 
sample data. However, for the analysis of unpredictable (tumour) samples, these 
provided reference probes may be inadequate. Thus, we created an algorithm 
that will select the 5 most stable reference probes and suggest that these probes 
be used for the normalisation of the traces. The user has full control over the 
settings of the analysis, and changes like including or excluding samples or 
designating probes as reference probes result in immediate recalculations. All 
calculations can be visualised in plots. By authorising the results, the analysis 
settings are definitively linked to the analysis and can no longer be changed. 
MLPA results are, in general, very reproducible. Still, we perform all tests at 
least in duplicate, especially in a diagnostic setting. MLPAinter supports the 
handling of replicates in the analysis. We previously validated the statistics used 
for MLPAinter on a series of DNAs that were obtained from formalin fixed and 
paraffin embedded oligodendroglial tumours by correlating the results with those 
obtained by fluorescent in situ hybridisation (FISH). The MLPA results were 
reproducible in all samples in which repeated experiments were performed. [9]
CONCLUSIONS
We have combined the analysis, visualisation and data management for MLPA 
in a tool, MLPAinter for MLPA interpretation, which makes use of a relational 
database with a Delphi front end. This integrated approach helps in the 
automated handling of large series of MLPA data and helps to guarantee a quick 
and streamlined dataflow from the initiation of an experiment to the generation 
of authorised report. MLPAinter has been successfully used in our lab for over 
two years to manage over 3000 samples. Moreover, different MLPA kits have 
been successfully used for this type of analysis, e.g., Kit P088 and P105 for the 




Project home page: http://code.google.com/p/mlpainter/ 
Operating system(s): Windows XP or higher
Programming language: Delphi
Other requirements: no
Licence: GNU GPL 3.0
Any restrictions to use by non-academics: no
ABBREVIATIONS
MLPA: Multiplex Legation-Dependent Probe Amplification, RFU: relative 
fluorescent units, RT-PCR: Real Time-PCR, MAD: median of the absolute 
deviations.
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KRAS is a small GTPase that plays a key role in Ras/MAPK signaling; somatic 
mutations in KRAS are frequently found in many cancers. The most common 
KRAS mutations result in a constitutively active protein. Accurate detection of 
KRAS mutations is pivotal to the molecular diagnosis of cancer and may guide 
proper treatment selection. 
We describe a two-step KRAS mutation screening protocol that combines whole 
genome amplification (WGA), high resolution melting analysis (HRM) as a 
prescreen method for mutation carrying samples, and direct Sanger sequencing 
of DNA from formalin-fixed, paraffin-embedded (FFPE) tissue, from which limited 
amounts of DNA are available. We developed target-specific primers, thereby 
avoiding amplification of homologous KRAS sequences. The addition of Herring 
Sperm DNA facilitated WGA in DNA samples isolated from as few as 100 cells. 
We show that KRAS mutation screening using HRM on wgaDNA from FFPE 
tissue is highly sensitive and specific; additionally, this method is feasible for 
screening of clinical specimens, as illustrated by our analysis of pancreatic 
cancers. Furthermore, PCR on wgaDNA does not introduce genotypic changes, 
as opposed to unamplified genomic DNA. This method can, after validation, be 
applied to virtually any potentially mutated region in the genome.
Introduction
Kirsten RAS (KRAS) is a member of the Ras gene family, which encodes small 
G proteins with intrinsic GTPase activity. These proteins play a key role in Ras/
MAPK signaling, which is involved in multiple pathways including proliferation, 
differentiation, and apoptosis. It has been suggested that KRAS mutations are 
related with a random CpG island methylation pattern which may lead to CpG 
island methylator phenotype (CIMP)-low tumors (1). KRAS is an important 
etiological factor in many cancers. Somatic mutations in KRAS are found in 75-
90% of pancreatic adenocarcinomas, 35-50% of colorectal carcinomas, and 30% 
of lung adenocarcinomas. In other cancers, KRAS mutations are less frequent or 
only present in specific subsets, such as subsets of bladder, endometrial, thyroid, 
and liver cancers (2-5). Mutations in KRAS negatively predict success of anti-
EGFR therapies. Gain-of-function KRAS mutations lead to EGFR independent 
activation of intracellular signaling pathways, resulting in tumor cell proliferation, 
protection against apoptosis, increased invasion and metastasis, and activation 
of tumor induced angiogenesis (6). 
The most common KRAS mutations are found in exon 2 (codons 12 and 13) and, 
more rarely, in exon 3 (codons 59 and 61). These mutations alter the conformation 
of KRAS, causing impaired GTPase activity that results in constitutive activation 
of the protein (7). Accurate detection of KRAS mutations is pivotal to the molecular 
diagnosis of cancer and may guide proper treatment selection. KRAS mutation 
analysis has been shown to be important for disease stratification in clinical trials 
of EGFR inhibitors (8;9), and for the detection of MUTYH mutants after KRAS 
mutation pre-screening (10). In the near future, it is expected that at least 50% of 
all recurrent colorectal tumors will be screened for KRAS mutations.
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Various methods have been described for the detection of KRAS mutations, such 
as a mutagenic PCR assay (11), pyrosequencing (12), and real time PCR (13); 
however, Sanger sequencing on PCR products remains the golden standard.
(6;14;15) Recently, high-resolution melting analysis (HRM) was added as a 
method for mutation scanning and genotyping (16-18), including analysis of 
KRAS mutations in heterogenic tumor populations. This method is a valuable 
addition to Sanger based sequencing, as it detects heterozygous genetic changes 
in samples containing only 10% of mutant cells (19-21), whereas direct Sanger 
sequencing requires the mutation to be present at a level of 20% of the sample.
(20) HRM has also been described for methylation detection and the detection of 
internal tandem duplications (22;23). In addition, HRM has a high sensitivity and 
specificity for the detection of variants in a background of normal DNA (24;25).
For mutation analysis, the majority of tissues are available as formalin-fixed, 
paraffin-embedded (FFPE) material. The genomic DNA (gDNA) that can be 
isolated from FFPE tissue is usually fragmented due to formalin fixation. At the 
same time, for most cases, including pre-operative biopsies, the available (FFPE) 
tissue, and thus gDNA, is limiting. As a result, the number of genetic assays that 
can be performed is restricted (26;27). 
One approach designed to overcome this limitation is whole genome amplification 
(WGA), which ideally generates a new whole genome sample of amplified DNA 
(wgaDNA) that is indistinguishable from the original, but with a higher DNA 
concentration (28). We used a primer extension pre-amplification (PEP) method 
that has been successfully applied to formalin-fixed paraffin-embedded (FFPE) 
tissue (29;30). We have studied HRM as a pre-screening method for somatic 
mutation detection in combination with WGA on gDNA from FFPE tissue. This 
approach is sensitive and specific and can open the archives for large scale 
mutation analysis (31-34). 
Materials and methods
Samples
We previously performed somatic KRAS mutation analyses in a series of 
colorectal cancers (35). A subset of 60 tumors (14 FF and 46 FFPE) was used 
to determine the sensitivity and specificity of the assay on FF and FFPE tissue. 
The tumor cell percentage in the series was 50-80%. Additionally we isolated 
gDNA from five pre-operative biopsies from pancreatic adeno-carcinomas and 
three 0.3 mm tissue punch cores that were isolated from matching resection 
specimens. Guided by an H&E stained section, the extremely small tumor fields 
were dissected from the biopsies. 
DNA was extracted using a standard proteinase K method as described elsewhere 
(36). All samples were handled according to the medical ethical guidelines 
described in the Code Proper Secondary Use of Human Tissue established by 




gDNA concentrations were measured using PICOgreen (Invitrogen/Molecular 
Probes, Leiden, The Netherlands) according to the manufacturer’s protocol. For 
WGA and PCR, gDNA is brought to a standard concentration of 5 ng/µL in 10 mM 
Tris, pH 8.0, 0.1 mM EDTA, and is stored in 2D bar-coded sample tubes (Thermo 
Fisher Scientific, NH, USA) for process standardization and robotic analysis.
Whole genome amplification 
Primer extension pre-amplification (PEP) WGA using thermo stable DNA 
polymerases (Kbioscience, UK) was carried out according to the manufacturer’s 
protocol using 25 ng gDNA in a final reaction volume of 25 µL. For FFPE samples 
and other samples from which limited gDNA was available, herring-sperm DNA 
(Promega) was added to a final concentration of 2 ng/µL per reaction. Thermal 
cycling was performed in a Biorad I-cycler. After an initial denaturation step of 
10 minutes at 94oC, 40 cycles of 30 seconds at 94oC, 30 seconds at 37oC, and 
ramping at a speed of 0.1oC /sec to 55oC, and 4 minutes at 55oC were performed. 
Mutation scanning and detection
Oligonucleotides were obtained from Operon (Germany). The primer sequences 
for the amplification of KRAS codons 12 and 13 were
KRAS_C1213_M13F 5’-(TGT AAA ACG ACG GCC AGT-TCG ACC CAG GAT 
CCA ACT T-GCT GAA AAT GAC TGA ATA TAA ACT TG)-3’ and KRAS_C1213_
M13R 5’-(CAG GAA ACA GCT ATG ACC ATG A-TCC AGT ACT TGA GAG 
AAT TCC ATC-TAG CTG TAT CGT CAA GGC ACT C)-3’. Stuffer sequences 
(underlined), were added between M13 tails (in italics) and the KRAS-specific 
part (bold) of the primer. The total length of the amplicon, inclusive of the M13 
tails and stuffers, is 166 base pairs. 
Duplicate PCR reactions were carried out in 10 µL reactions in white 96 well 
plates (AB0800/W, ABgene) that are suitable for HRM. The reactions included 
iQ Supermix (Bio-Rad, cat nr 170-8860), 2 pmol primers and 1 µM SYTO9 
(Invitrogen). PCR reactions were performed with an initial denaturation step of 
10 minutes at 95oC, followed by 40 cycles of 5 seconds at 95oC, 10 seconds at 
60oC, and 10 seconds at 72oC, and a final elongation step of 10 minutes at 72oC.
Sanger DNA sequencing was performed on gDNA and wgaDNA at the sequence 
core of the Leiden Genome Technology Center, using the same PCR products 
as those submitted to HRM. Prior to Sanger sequencing PCR fragments were 
purified using a filter system according to the manufacturer’s protocol (Montage, 
Millipore). DNA was eluted in 25 µL of sterile water. Sanger sequencing was 
subsequently performed with 5-10 ng of DNA and 6 pmol of an M13 primer (PR_
M13F TGTAAAACGACGGCCAGT and PR_M13R CAGGAAACAGCTATGACC) 
on an ABI 3700 DNA Analyzer using Big Dye Terminator Chemistry (Applied 
Biosystems). All sequences were visually analyzed with Mutation SurveyorTM 
DNA variant analysis software (version 2.61 Softgenetics, State College, PA). 
HRM was performed in a LightScanner (Idaho Technology) after the addition of 
15 µL of mineral oil (Sigma); Light Scanner software (version 1.1.0.566, Idaho 
Technology) was used for analysis. High salt addition (24); 1.5 µL of 1M KCl 
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and 0.5M Tris-HCl, pH 8.0, was added post-PCR to the 10 µL PCR products 
followed by 4 additional temperature cycles (30 seconds 94˚C, 30 seconds 72˚C). 
The sensitivity and specificity of the HRM were calculated. The sensitivity was 
determined as the number of true positives divided by the sum of the true positive 
and false negative samples. The specificity of the samples was determined as 
the number of true negatives divided by the sum of the true negatives and false 
positives. Mineral oil overlay, high salt addition, and PCR product purification was 
performed in a post-PCR setting.
Results
Detection of KRAS mutations in genomic DNA using HRM
KRAS PCR and HRM analyses were performed on gDNA in duplicate before 
and after the addition of high salt. All duplicate samples with an aberrant melting 
pattern were identified as carrying a possible mutation. The data were compared 
with the Sanger sequencing results. An overview of the results is shown in Table 
1. `Six FFPE samples (5%) failed to give an interpretable HRM pattern in one 
of the duplicates. None of these gave contradictory sequence results and were 
included in further analysis. (Supplementary table 1 at http://jmd.amjpathol.org)
In the set of 60 tumors we observed an overall sensitivity of 100% (33/33) and a 
specificity of 81% (22/27) for the detection of KRAS codon 12 or 13 variations. 
The specificity of gDNA from FFPE tissue (75%; 15/20) was lower than in FF 
tissue (100%; 7/7), probably as a result of poor gDNA quality intrinsic to the 
material (Table 2). 
HRM on whole genome amplified (WGA) DNA from archival tissues
To evaluate the sensitivity and specificity of HRM on WGA-treated DNA from 
tumor specimens of different origins and quality, we performed WGA on the gDNA 
samples with known KRAS mutation status. To assess the DNA quality pre- and 
post-WGA, a multiplex PCR containing 3 fragments (150, 255, and 511 base 
pairs) was carried out. In all of the samples at least the 255-bp band was visible 
(data not shown).
Herring Sperm DNA was added up to 50 ng to all samples prior to WGA as driver 
DNA to prevent the amplification of excess small random PCR products 
After WGA, 1:1, 1:5, and 1:10 dilutions of the wgaDNA were made to determine 
the amount of input wgaDNA that was required for HRM PCR. The addition of 2 µl 
of the 1:5 dilution to a 10 µl PCR gave the best results and we were able to detect 
the different mutations in control samples (Figure 1). 
We combined 25 ng gDNA with 25 ng Herring Sperm DNA in each WGA reaction 
for the subset of 60 tumors. In these experiments, the researchers were blinded 
to the HRM and Sanger sequence results obtained for the gDNA samples. 
Subsequently, KRAS PCR was performed in duplicate, and HRM analysis was 
performed before and after high salt addition. Three samples (2.5%) failed to give 
an interpretable HRM pattern in one set of the duplicates. For each product, one 
of the duplicates was purified and Sanger sequenced. HRM and re-sequencing 
of the WGA PCR samples revealed no discrepancies with the original samples 
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ID Type gDNA wgaDNA (g-wga)DNA
   (no salt) Sequencing
972 FF Var Var (FN) c12. GGT>GTT 
755 FF WT FP (WT*) WT 
819 FF WT WT (FP) WT
826 FF WT WT (FP) WT
977 FFPE Var Var (FN) c13. GGC>GAC 
998 FFPE Var Var (FN*) c13. GGC>GAC 
811 FFPE Var Var (FN) c12. GGT>GAT 
761 FFPE Var Var (FN) c12. GGT>GTT 
768 FFPE Var Var (FN) c12. GGT>GTT 
785 FFPE Var Var (FN) c12. GGT>GTT 
806 FFPE Var Var (FN*) c12. GGT>GTT 
013 FFPE FP WT (WT) WT
023 FFPE FP WT (WT) WT
750 FFPE FP* WT (FP) WT
958 FFPE FP WT (WT) WT
975 FFPE FP* WT (WT) WT
Table 1. False positives and false negatives in KRAS (wga) HRM and sequencing. 
Overview of false positives (FP) and false negatives (FN) in HRM performed with or 
without WGA. In the wgaDNA column, the HRM results on samples without the addition 
of high salt are shown between brackets. HRM results after the addition of a high salt 
solution on samples performed in duplicate (results for samples marked with * are based 
on a single result). The last column shows the concordant gDNA and wgaDNA results of 
Sanger sequencing on one of the duplicates. The complete overview of all tested samples 
is listed in Supplementary Table 1. FF; Freshly Frozen tissue, FFPE; formalin fixed paraffin 
embedded tissue, Var; KRAS-variant, WT; KRAS wild-type. 
Table 2. Sensitivity and specificity in (wga)HRM. Sensitivity and specificity calculated for 
HRM in FFPE, Freshly Frozen (FF) and combined FFPE and FF gDNA and wgaDNA 
samples in the presence of high salt. In the wgaDNA columns, HRM results on samples 
without the addition of high salt are shown between brackets. FP, false positives; FN, false 
negatives; Var, KRAS-variant; WT, KRAS wild-type. 
FFPE FFPE FF FF     Com  -  bined
DNA type gDNA wgaDNA gDNA wgaDNA gDNA wgaDNA
WT 15 20 (19) 7 6 (5) 22 26 (24)
Var 26 26 (19) 7 7 (6) 33 33 (25)
FN 0 0 (7) 0 0 (1) 0 0 (8)
FP 5 0 (1) 0 1 (2) 5 1 (3)
overall 46 14 60
% Sensitivity 100 100 (73) 100 100 (86) 100 100 (76)
% Specificity 75 100 (95) 100 86 (71) 81 100 (89)
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(Table 1 and Supplementary table 1 at http://jmd.amjpathol.org). The sensitivity 
and specificity of the HRM was calculated. WGA-HRM proved to be 100% (33/33) 
sensitive and 96% (26/27) specific in the presence of post-PCR high salt. Without 
high salt, the sensitivity and specificity were lower (76% (25/33) and 89% (24/27), 
respectively).(Table 2)
Detection limits for HRM of wgaDNA
To determine the limits of HRM to detect a possible KRAS mutation in wgaDNA 
from FFPE tissue, we performed WGA on a two-fold serial dilution of gDNA 
carrying a g.35GGT>GTT (p.12G>V) mutation. The gDNA input ranged from 10 
ng to 0.08 ng, the latter corresponding to the gDNA equivalent of approximately 
10-12 cells. After WGA, HRM was performed in duplicate on WGA samples diluted 
1:5. A mutant allele was detected in WGA products corresponding with 600 pg 
(equivalent to approximately 100 cells) or higher. HRM on wgaDNA originating 
from lower input gDNA resulted in low fluorescence of the mutant allele, thus 
impairing the analysis and interpretation. We performed direct Sanger sequencing 
on all wgaDNA samples. The KRAS mutation was found in all dilutions, although 
the mutant allele was difficult to identify due to background noise in samples 
with lower than 600 pg input gDNA. KRAS mutations were easily detected in 
sequences from WGA PCR isolates corresponding to 100 cells or more (Figure 
2) (29).
KRAS mutation detection in pancreatic adenocarcinomas
We further evaluated KRAS HRM and Sanger sequencing in wgaDNA from 
archived clinical specimens. gDNA from pancreatic adenocarcinomas was 
isolated from a single slide (samples 1a-4a) and from four combined slides (1b-
4b). For comparison, we also isolated gDNA from three 0.3 mm tissue punch 
cores that were isolated from matching resection specimens. After gDNA 
isolation, this sample was split into a minor (5f) and major (5p) fraction; the major 
fraction contained a 6-fold higher gDNA concentration. As expected, the gDNA 
concentrations of the isolates were low or not measurable (Table 3). Subsequently, 
WGA was performed on the fractions, and, HRM and Sanger sequencing were 
performed on the wgaDNA. For the samples 1b and fp, gDNA was also tested. 
WGA was performed on 10 ng gDNA and adjusted to 50 ng with Herring Sperm 
DNA. For samples where the gDNA concentration was not measurable 15 µl of 
the raw isolate was added to the WGA reaction together with 50 ng with Herring 
Sperm DNA. HRM revealed concordant KRAS-variant curves in samples 5f and 
5p, while samples 1a and 1b gave contradictory results for HRM. The variant 
curves for sample 3b were interpretable, while the signals for samples 2a, 2b, 3a, 
4a, and 4b were low and could not be interpreted. Purification and re-sequencing 
of all of the HRM PCR products was possible in all cases, and revealed that 
samples 2 and 5 carried the g.35G>A (p.G12D) mutation, sample 3 was a 
g.35G>T (p.G12V) mutant, and samples 1 and 4 were wild-type. These results 
indicated that the HRM results for sample 1a were false positive (Table 3). 
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Figure 1. HRM curves 
in samples treated 
with or without WGA. 
HRM shifted melting 
curves and difference 
curves of 3 different 
KRAS codon 12 and 13 
mutations in duplicate, 
with or without WGA 
treatment. g.35G>A 
(p.12G>D) DNA lower 
green, wgaDNA upper 
green; g.38G>A 
(p.13G>D) DNA 
lower blue, wgaDNA 
upper blue; g.35G>T 
(p.12G>V) red; and a 
series of 8 wild-type 
samples (gray). 
Figure 2. Detection limit of KRAS mutations in a PCR of serial diluted wgaDNA. Left panel: 
2-fold serial dilution of gDNA starting with 0.08 ng input (lowest curve) to 10 ng (upper 
curve) shows the detection limit for KRAS mutations in a PCR on wgaDNA. Upper right 
panel: Sanger sequence on wgaDNA corresponds with 10 ng gDNA input in the WGA. 
Lower right panel: Sanger sequence on wgaDNA corresponds with 0.625 ng (+/- 100 cells) 
gDNA input in the WGA. 
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Discussion
Accurate detection of KRAS mutations is pivotal to the molecular diagnosis of 
cancer and may guide proper treatment selection. We have developed a standard 
WGA and PCR protocol for KRAS mutation detection in gDNA derived from FFPE 
tissue, for which limited amounts of gDNA are available. High resolution melting 
analysis (HRM) is used for mutation prescreening and Sanger sequencing is 
used for mutation detection. 
The most frequently mutated codons, 12 and 13, in exon 2, are located in a 
region that is highly homologous to regions on chromosomes 6 and 16. To 
prevent the amplification of pseudogene sequences we used primers based on 
non-homologous nucleotides (10;37;38). Addition of universal M13 tails to the 
primers increased the specificity and fidelity of the PCR (10;39) and allows the 
use of uniform sequencing primers. Since the KRAS amplicon length is only 75 
nucleotides and short PCR fragments can be difficult to sequence, we added 
additional stuffer sequences to the primers, between the M13 tails and the KRAS-
specific part of the primer. These stuffers bear no homology to any known human 
sequence. Since the amplicons are very small, the length of each step of the PCR 
cycle was shortened, resulting in a 40 cycle PCR that lasted just over 1 hour.
We evaluated LCGreen and SYTO9 for HRM and found that both dyes were 
capable of detecting different KRAS variations. SYTO9 has been reported to have 
some advantages in terms of dye stability, dye-dependent PCR inhibition, and 










1a 1 2.2 VAR WT
1b 4 9.9 WT WT
2a 1 <2 Low Signal c12. GGT>GAT
2b 4 2.9 Low Signal c12. GGT>GAT
3a 1 <2 Low Signal c12. GGT>GTT
3b 4 3.3 VAR c12. GGT>GTT
4a 1 <2 Low Signal WT
4b 4 <2 Low Signal WT
5f fraction <2 VAR c12. GGT>GAT
5p 3 punches 12.1 VAR c12. GGT>GAT
 
Table 3. WGA HRM results in histological specimens from pancreatic adenocarcinomas. 
Concentration measurements are performed on gDNA isolates from a single slide (samples 
1a-4a), from four combined slides (samples 1b-4b), and from a matching resection 
specimen with minor (5f) and major fractions (5p). For a number of samples the gDNA 
concentration was not measurable (low). WGA is performed on all samples. HRM results 
in the presence of high salt. Samples marked Low Signal had an unclear HRM pattern. 
The last column shows the KRAS Sanger sequencing results on the purified HRM sample.
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PCR (40). In our experiments, SYTO9 appeared to improve the quality of the 
melting curves, since the fluorescence signal was approximately 50% higher and 
the duplicate curves fit more tightly together. Therefore, we decided to use SYTO9 
in subsequent experiments (Supplementary Figure S1 http://jmd.amjpathol.org). 
It has been reported that high-resolution analysis of amplicon melting is limited 
by any Tm variance, including differences in salt concentrations (arising from 
evaporation during processing or differences in buffers used for DNA preparation), 
and any variation in instrument temperature (41). Furthermore, poor DNA quality, 
low input, and positional effects of the samples on the microtiter plate might lead to 
false positive or false negative HRM measurements (42). Therefore, all samples 
were analyzed in duplicate. For calibration, at least two wild-type samples were 
analyzed in each experiment.
We observed an overall sensitivity of 100% (33/33) and a specificity of 81% (22/27) 
for the detection of KRAS codon 12 or 13 variations. However the specificity of 
gDNA from FFPE tissue (75%,15/20) was lower than in FF tissue (100%, 7/7), 
probably as a result of poor gDNA quality intrinsic to the material (Table 2). From 
the melting curve behavior, it was not possible to determine the specific mutation, 
likely due to tumor percentage and tumor heterogeneity. Consequently, all 
samples with possible mutations were Sanger sequenced in order to identify the 
nature of the mutation. Sanger sequencing was directly performed on the purified 
HRM PCR product without repeating the PCR, which is time, and costs saving. 
KRAS mutations are frequently found in ductal pancreatic cancers (4) making it 
important in clinical practice to identify KRAS mutations in cytological, pancreatic 
juice with only minimal amounts of cells and limiting (FFPE) gDNA (26;27;43). 
One approach designed to overcome the limited number of assays possible 
on this material is whole genome amplification (WGA). Different types of WGA 
methods are available. Strand displacement amplification (SDA or MDA) has 
been described as most reliable for genotyping, giving highest call rates, best 
genomic coverage and lowest amplification bias. However this method has the 
disadvantage that the specific performance largely depends on input DNA quality 
making it less suitable to efficiently amplify DNA extracted from FFPE material 
(44). Primer extension pre-amplification PEP based WGA has been successfully 
applied to FFPE tissue. (29;30) although some bias as result of the WGA has 
been observed (12). We used a PEP based WGA method that is known to have 
high sequencing accuracy and is less dependent upon the quality of the input 
DNA (45) however we observed that, with low amounts of input (< 10 ng) gDNA 
and with poor quality FFPE samples, the random primers in the WGA produce 
excess random wgaDNA and primer dimer products. These additional products 
impaired HRM and subsequent Sanger sequencing. Therefore, we added non 
homologous Herring Sperm to the human DNA, for all samples prior to WGA 
to suppress primer dimer formation. The combined human and herring DNA 
input in the WGA reaction was approximately 50 ng. Herring Sperm DNA has 
low homology to human KRAS and we did not detect any PCR product with the 
described primers in a control PCR. Therefore, herring sperm DNA addition should 
not interfere with KRAS HRM or Sanger sequencing. We compared the Sanger 
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sequencing results on gDNA and wgaDNA. This did not reveal any discrepancies 
and showed that KRAS mutation screening using HRM on wgaDNA from FFPE 
tissue is concordant with the non-wgaDNA results. With this approach, we were 
able to WGA minimal amounts of gDNA with reliable results. We observed that 
with less than 2 ng of FFPE-derived gDNA input in the WGA reaction HRM on 
wgaDNA becomes unreliable. The PCR products still produced reliable Sanger 
sequences. This was also demonstrated by the pancreatic adenocarcinomas 
which failed for HRM but gave good Sanger sequence results. This showed that 
HRM is very sensitive for DNA variants, however, to obtain interpretable results 
higher amounts of DNA are required in the HRM than in Sanger sequencing 
(Table 3).
We optimized HRM in wgaDNA by the post-PCR addition of high salt (24). 
This resulted in enhanced heteroduplex formation, better discrimination of the 
mutation carrier during analysis, and 100% sensitivity and 96% specificity. Cho et 
al 2008 (34) reported that HRM on wgaDNA results in a higher fals positive rate 
and reduced sensitivity and specificity. We show that high-salt addition prior to 
analysis overcomes this problem, thereby making this approach suitable for high 
throughput mutation pre-screening.
A potential disadvantage of our method could be that PCR plates need to be 
opened prior to analysis, to add mineral oil and high salt solution, although 
opening the plates for PCR cleanup prior to sequencing is standard practice. To 
minimize the chance of PCR amplicon contamination pre, and post PCR rooms 
were strictly separated and we used a direct PCR reaction to avoid pseudogene 
amplification rather than nested PCR for KRAS mutation detection (37;46). 
Another factor to consider is tumor heterogeneity. In samples with lower tumor 
percentage and low amount of the mutated allele, automated Sanger sequence 
analysis could miss variants while HRM could still detect mutations in gDNA and 
wgaDNA from samples with low tumor percentages. Vossen et al show that DNA 
variations could be detected in sample mixtures with as little as 5% variation 
fraction, although 30% and higher gave more reliable results in HRM (24). 
Because HRM in samples with unknown tumor percentage is limited in predicting 
the exact KRAS variant, samples with HRM variations have to be sequenced 
for variant determination. A combination of low tumor percentage and low input 
concentrations in the WGA might cause HRM dropout or contradictory results in 
the duplicate reactions, making careful (re)analysis of the Sanger sequencing 
indispensable (Figure 2). For this type of samples alternative mutation detection 
after HRM pre-screening should be considered such as pyrosequencing which 
is known to be more sensitive than Sanger sequencing (12). Allele specific real 
time PCR is also a very sensitive method but it has the disadvantage of detection 
known (KRAS) variants only while our approach envisions application for denovo 
mutation screening (47). For this type of samples sensitivity and specificity have 
to be calculated in relation to results obtained with pyrosequencing or real time 
PCR. 
One can argue that the majority of laboratories can obtain a sufficient amount of 
DNA for KRAS mutation screening from even tiny biopsies without the WGA step. 
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This assertion might be true in some cases. However, in a time when personalized 
medicine is the norm, KRAS mutation detection may be one test in a series of 
many and in that respect, WGA may be an excellent method by which to increase 
the initial amount of DNA that can be used for the analysis of any potentially 
mutated region in the genome. (48)
Finally, the required equipment for this approach is limited to two standard 
thermal cyclers (one dedicated to WGA and another in a separate room for PCR), 
dedicated HRM equipment, and a sequencing facility. HRM on wgaDNA from 
FFPE origin can be a cost effective pre-screening method, since only potential 
variants found after HRM need re-sequencing. Therefore, HRM, in combination 
with WGA and sequencing, is a strong tool for KRAS mutation screening of 
samples with partially degraded or low yield DNA, as is often found in pathology 
archives. 
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Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-
TBNA) and Trans-esophageal Ultrasound Scanning with Fine Needle Aspiration 
(EUS-FNA) are important, novel techniques for the diagnosis and staging of non-
small cell lung cancer (NSCLC) that have been incorporated into lung cancer 
staging guidelines. To guide and optimize treatment decisions, especially for 
NSCLC patients in stage III and IV, EGFR and KRAS mutation status is often 
required. The concordance rate of the mutation analysis between these cytological 
aspirates and histological samples obtained by surgical staging is unknown. 
Therefore, we studied the extent to which allele-specific quantitative real-time 
PCR with hydrolysis probes could be reliably performed on EBUS and EUS fine 
needle aspirates by comparing the results with histological material from the 
same patient. We analyzed a series of 43 NSCLC patients for whom cytological 
and histological material was available. We demonstrated that these standard 
molecular techniques can be accurately applied on fine needle cytological 
aspirates from NSCLC patients. Importantly, we show that all mutations detected 
in the histological material of primary tumor were also identified in the cytological 
samples. We conclude that molecular profiling can be reliably performed on fine 
needle cytology aspirates from NSCLC patients.
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Introduction
Lung cancer is the leading cause of cancer mortality in the Western world [1]. 
For clinical and therapeutic purposes, lung cancer is traditionally subdivided 
into small cell (SCLC) and non-small cell lung cancer (NSCLC). Whereas SCLC 
is treated by chemo- and/or radiotherapy, NSCLC is primarily treated through 
resection; however, only 30% of NSCLC patients have a resectable disease 
(stage I/II) at the time of presentation [2]. This underscores the importance of 
accurate, preoperative mediastinal staging in preventing unnecessary resections. 
Preoperative staging can be performed through the transbronchial (EBUS-TBNA) 
or transesophageal (EUS-FNA) aspiration of the mediastinal lymph nodes. These 
cytological procedures are less invasive than routine mediastinoscopy followed 
by biopsy of the lymph nodes, but similar high specificity and sensitivity [3–9] 
are achieved. Endosonography has been incorporated into lung cancer staging 
guidelines as an alternative for the surgical staging of the mediastinum [10,11].
In many cases, the increased use of these minimally invasive techniques 
is sufficient to diagnose and stage the patient correctly. Although the amount 
of cellular material obtained by these procedures is relatively small, the 
information requested by the clinicians is rapidly growing, e.g., for NSCLC, 
immunohistochemistry and molecular pathology have become part of the 
standard care [12]. 
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In addition to this change in staging procedures, the rapid development of new 
medical treatments for NSCLC patients has taken place. A subset of NSCLC 
cancers may harbor an activating mutation in the EGFR kinase domain [13]. 
Tumors with these mutations are frequently sensitive to tyrosine kinase inhibitors 
(TKIs). On the other hand, activating mutations in KRAS are associated with 
resistance to TKIs. Although most publications report that these mutations are 
mutually exclusive [14–19], evidence suggests [20] that a tumor can simultaneously 
harbor an activating EGFR mutation and mutations downstream in the pathway 
in the KRAS gene, which means that upstream inhibition of EGFR will have 
no therapeutic effect in these cases. Also, mutations in BRAF and PIK3CA are 
reported in NSCLC. However, further research is required to determine the extent 
to which these mutations can have consequences for treatment [21,22].
Due to these developments and the desire of patients and clinicians to minimize 
the delay of treatment, rapid and sensitive molecular techniques are needed. 
Preferably, these techniques should be applicable on formalin-fixed, paraffin-
embedded (FFPE) cytological samples [23–25] because EBUS-TBNA and EUS-
FNA aspiration samples are often the first material that is acquired from patients 
with NSCLC. Allele-specific quantitative real-time PCR (qPCR) with hydrolysis 
probes is a reliable and sensitive technique that can be used for this purpose. 
Detecting mutations in EGFR, KRAS, BRAF and PIK3CA with hydrolysis probes 
has been previously described in NSCLC patients [23–26]. The sensitivity of the 
assays also surpasses the 1% sensitivity proposal set for KRAS mutation testing 
[27] .
The majority of EGFR mutations are p.L858R, the hotspot mutation in exon 
21 and deletions in exon 19, which are reported to comprise up to 36% of all 
activating mutations [15,28]. KRAS is mutated in 10%–30% of lung carcinomas 
and over 95% of all activating mutations in KRAS are located in exon 1 (codons 
12 and 13) [28,29]. The BRAF p.V600E hotspot mutation is reported in 3% of 
NSCLC and alters residues important in AKT-mediated BRAF phosphorylation, 
suggesting that the disruption of AKT-induced BRAF inhibition plays a role in 
malignant transformation [28,30]. Three hotspot mutations in PIK3CA may be 
another cause of the over-activation of the PI3K–AKT pathway, which promotes 
the malignant transformation of human airway epithelial cells and has been 
reported in approximately 4% of lung carcinomas [28,31]. 
In the current study, we compared allele-specific qPCR assays for the most 
frequent activating mutations in EGFR, KRAS, BRAF and PIK3CA in tumor-
positive fine needle cytological aspirates against histological material of primary 
tumors.
With this approach, we aimed to determine the extent to which allele-specific 
qPCR with hydrolysis probes can be performed on cytological aspiration material 
by comparing the mutation status and then observing the concordance rate 






Specific need for ethics committee’s approval was not necessary for this study. 
All samples were handled according to the medical ethical guidelines described 
in the Code Proper Secondary Use of Human Tissue established by the Dutch 
Federation of Medical Sciences (www.federa.org, accessed October 27, 2010). 
Accordingly to these guidelines all human material used in this study has been 
anonymized since clinical data were not used. Because of this anonymization 
procedure individual patients’ permission is not needed.
Sample selection
Material from 43 patients with NSCLC for which both tumor-positive cytological 
and histological material was available were selected from the Department of 
Pathology in the Leiden University Medical Center (LUMC) and identified through 
a PALGA database search; non-gynecologic cytological samples between 2005 
and 2009 were searched using the search-strings “lung, malignant cells and non 
small cell lung cancer” and “mediastinum, malignant cells and non small cell 
lung cancer”. From the 447 unique cytological samples, we selected cases for 
which tumor-positive histological material of the primary tumor was also available 
(Supplementary Table S1). Of the 43 patients, 33 patients were subtyped: 14 
squamous cell carcinomas, 15 adenocarcinomas, 3 adenosquamous carcinomas 
and 1 large cell carcinoma. The remaining 10 patients had been classified NSCLC 
only. 
DNA from 42 control FFPE samples was obtained from the Molecular Diagnostics 
(MD) section of the Department of Pathology in the LUMC. For validation 
purposes, a series of 10 DNA samples, of which 9 had a demonstrated EGFR 
exon 19 deletion by DNA sequencing, was provided by the Netherlands Cancer 
Institute - Antoni van Leeuwenhoek Hospital.
DNA isolation 
Prior to DNA isolation, tumor cells were enriched to obtain tumor cell percentages 
> 70% (Figure 1). The FFPE tumor blocks were enriched for tumor cells guided 
by a hematoxylin and eosin (H&E)-stained slide taking 0.6-mm tissue punches 
from the tumor focus in the FFPE block by using a tissue microarrayer (Beecher 
Instruments, Sun Prairie, WI, USA). Prior to DNA isolation, the tissue was 
deparaffinized in xylene and washed in 70% ethanol. For the cell blocks, 10 slides 
of 10 mm were stained with hematoxylin. Tumor cells were marked by guiding with 
a 5-mm H&E slide and the corresponding tumor fields on the hematoxylin slides 
were microdissected. 
For the cytology smears, microdissection was initiated by marking the tumor foci 
with a diamond needle on the back side of the Giemsa-stained slide. Subsequently, 
cover slips were removed by incubating in xylene at room temperature in separate 
50-ml tubes to avoid contamination. Incubation was performed overnight or until 
the cover slip was removed (sometimes up to a week). Subsequently, the slides 
were washed in alcohol, three times in 100%, once in 70% and once in 50%, to 
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rehydrate the tissue. Using a scalpel blade, the tumor foci from the marked areas 
were scraped and collected in micro tubes for DNA isolation.
DNA was isolated using the NucleoSpin Tissue XS Genomic DNA Purification kit 
(Machery-Nagel, Düren, Germany) according to the manufacturer’s instructions. 
The average DNA yield from the cytological smears and cell blocks was 282 ng 
and 280 ng, respectively. However, cytology smears were fixed using methanol 
rather than formalin, so the isolated DNA was expected to be of higher quality. 
The average DNA yield from the biopsies was considerably higher (985 ng).
Prior to analysis, the DNA samples were diluted by 5 or 15 times. We observed 
that DNA diluted over 15 times generally gave a quantification cycle (Cq) > 35 
(data not shown); therefore, in the subsequent assays, we used 5x stock DNA 
dilutions in sterile water. 
Mutation detection 
The assays for the detection of seven different KRAS, three PIK3CA and one 
BRAF variant were obtained through the Custom TaqMan® Assay Design Tool 
(Applied Biosystems, Nieuwerkerk a/d IJssel, NL). Hydrolysis probes were 
designed with minor grove binder (MGB) modifications at the 3′-end. These 
modified probes have the advantage that relatively short probes can be designed 
with higher melting temperature (Tm) and increased duplex stability and specificity 
in comparison to conventional probes [32]. The EGFR assays were described 
previously [33]. qPCR reactions were performed in 10-µl reactions containing 
5 µl of FastStart Universal Probe Master (Roche Applied Science), 1 µl of 10x 
primer and hydrolysis probe solutions, 2 µl of 5x diluted DNA and 2 µl of sterile 
water in a sealed LightCycler 480 Multiwell Plate 384 (Roche Applied Science) 
in a LightCycler 480 system (Roche Diagnostics) as follows: 10 minutes at 95 °C 
and 45 cycles of 15 seconds at 92 °C, 60 seconds at 60 °C and 10 seconds at 
72 °C. For validation, we performed direct Sanger sequencing using M13 primers 
as described previously [34] at the sequencing core of the Leiden Genome 
Technology Center. Primer sequences are listed in Supplementary Table S2. All 
DNA Sequencing was completed on known genes and no new sequencing was 
completed.
Raw data from the LC480 software were imported into an in-house–created 
Microsoft Excel 2003 spreadsheet to define the mutation status. The quantification 
cycle (Cq) was used for quality assessment and samples with Cq values 
exceeding 35 (Cq>35) in the wild-type channel were rejected and excluded 
for further analysis. To determine the presence or absence of a mutation, the 
endpoint fluorescence ratio Rm/Rwt was calculated after subtracting the average 
background signal from three negative controls. The spreadsheet is available 
upon request. For BRAF, PIK3CA and EGFR p.L858R, mutation status was 
directly discriminated (Figure 2a). Mutations were identified when the Rm/Rwt ratio 
was higher than 0.7, while a ratio lower than 0.3 indicated the absence of a 
mutation. No intermediate values were observed. In KRAS wild-type samples, 
an increased background signal was observed for the c.34G>T (Rm/Rwt±0.4) and 
c.38G>C (Rm/Rwt±0.6) assay in the mutant probe channel. This was probably 
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Figure 1. Mediastinal lymph node cytology of a NSCLC patient. Microscopical detail of a 
cytological smear obtained through fine needle aspiration of a meadiastinal lymph node 
from a NSCLC patient. The tumor foci are marked on the backside of each slide with a 
diamond tip. Subsequently the coverslips are removed and tumor foci are scraped from 
the slide using a scalpel blade (not shown).
caused by imperfect hybridization of these probes to the wild-type allele. The 
setting to identify the mutation correctly was c.34G>T Rm/Rwt>0.7, while the 
c.38G>T mutant was identified when an Rm/Rwt ratio cut-off of 0.8 was used. The 
EGFR exon 19 deletion probe resulted in a drop in endpoint fluorescence, while 
in a wild-type sample, both probes gave a signal. To analyze EGFR exon 19 
deletions, Rm/Rwt>0.8 and Cq<32 were considered wild-type and Rm/Rwt≤0.6 and 
Cq<32 indicated a deletion. Intermediate values, with Rm/Rwt ratio between 0.6 
and 0.8 and Cq<35, required confirmation using Sanger sequencing.
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Results and discussion
Assay design and validation
For BRAF, a single assay was designed that detects the activating hotspot 
mutation p.V600E, which results from the c.1799T>A substitution [35]. For 
PIK3CA, we designed probes for the three most common substitutions [36]: 
c.1624G>A (p.E542K), c.1633G>A (p.E545K) and c.3140A>G (p.H1047R). 
Although these three assays detected over 85% of all mutations in NSCLC, some 
of the infrequent substitutions in the hotspot regions were potentially missed. For 
KRAS, we designed assays for the seven most frequent base pair substitutions in 
codons 12 and 13: c.34G>A (p.G12S), c.34G>C, (p.G12R), c.34G>T, (p.G12C), 
c.35G>A, (p.G12D), c.35G>C, (p.G12A), c.35G>T (p.G12V) and c.38G>A 
(p.G13D). Together, these assays detect almost all substitutions in KRAS, 
although some rare variants might be missed. To detect the p.L858R hotspot and 
exon 19 deletions in EGFR we used previously reported assays [33]. The EGFR 
p.L858R mutation was detected using a probe mix containing a wild-type probe 
and two different mutant probes: one for the most common variant (c.2573T>G) 
and one for the rare complex c.2573_2574TG>GT inversion. 
Hotspot mutation analysis in cytology material from NSCLC patients
To address the extent to which the mutation analysis can be reliably performed 
on EBUS-TBNA and EUS-FNA aspiration material, we performed the 13 assays 
on 43 patients with NSCLC for which both primary tumor (either biopsies or 
histological material from resections) and tumor-positive cytological material had 
been collected. The material from the 43 patients represents 29 tissue cores 
from histological excisions, 23 microdissected biopsies and 3 whole-section 
biopsies which were compared to 45 microdissected cytological smears and 17 
microdissected cell blocks (Supplementary Table S1).
Six patients presented with a KRAS mutation: c.34G>T (N=2), c.34G>A, c.35G>A, 
c.35G>C and c.38G>A. One patient carried a deletion in exon 19 of EGFR 
(c.2238_2252del15) and two patients showed PIK3CA mutations: c.1633G>A 
and c.3140A>G. The latter case showed an additional KRAS mutation (p.34G>T). 
No mutations in BRAF were observed. 
For some patients, multiple histological and/or cytological samples were 
analyzed. In different samples for the same patient, conflicting results for the 
same type of material were never observed. Therefore in table 1 each patient 
is represented only once, where for each type of material the information from 
all the patient’s samples is merged. This means that the clearest signal for each 
assay took precedence. In table 1, the remaining missing calls, due to low signals 
are indicated by “?”. 
The overall call rate in the 13 assays, after merging, amounts to 95% (58 
undetermined results out of 1118 tests). The call rate for histological material 
is substantially higher at 99% (8 undetermined out of 559) than for cytological 
material at 91% (48 out of 559). Within the cytological material, the call rate 
for primary tumors is lower (84%) than for metastases (96%). Note that these 
observations remain if the patient with the lowest quality results (sample 21) is 
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Figure 2. qPCR Results for the EGFR assays. Panel A shows the EGFR p.L858R assay. 
All samples show a wild type (control) signal, VIC, lower panel (green and blue lines) 
while only group 2 (blue line) shows a mutant FAM signal. Panel B shows the EGFR 
exon 19 mutation assay. The lower panel shows the wildtype VIC signal for all samples 
(red, green and purple lines). The top panels shows the mutant FAM signal. Group 1 (red 
lines) shows the wildtype signal, Group 2 (red and purple) shows possible mutants with 
decreased fluorescence, group 3 (green line) show an almost completely disappeared 
signal indicating a deletion. The images are obtained from the LC480 software release 
1.5.0.The y-axis shows the relative fluorescence for the FAM (465-510 nm) and VIC (533-
580nm) probes, x-axis shows the PCR cycles.
Figure 3. Effect of the 
DNA concentration on the 
c.34G>T KRAS assay. The 
top panel shows the mutant 
(FAM) signal for a range of 
different amounts of input 
DNA in pg carrying the 
c.34G>T KRAS mutation. No 
“mutant” signal is observed 
in a wildtype DNA (green 
line) and water control 
(grey line). In the wildtype 
(VIC) panel all DNA’s show 
a wildtype signal while the 
water control is negative 
(grey line). The images are 
obtained from the LC480 
software release 1.5.0. The 
y-axis shows the relative 
fluorescence for the FAM 
(465-510 nm) and VIC 
(533-580nm) probes, x-axis 
shows the PCR cycles.
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removed. Within the histological material the same difference in call rate can be 
observed, but in a much lower degree (98% for primary tumors versus 99% for 
metastases). When comparing call rates per assay, we observed that the three 
assays on the PIK3CA gene performed less (between 88 and 91%) than the 
other 10 assays (between 94 and 99%). 
As could be observed, when cytological material was obtained from primary 
tumors, the mutation results for histology and cytology were concordant in all 
cases where both results were determined. When cytological material was 
obtained from metastasis, in one patient (nr 40) with an adenocarcinoma/
bronchoalveolar cell carcinoma (BAC), a KRAS c.34G>A mutation was identified 
in the mediastinal lymph node which was not detected in the primary tumor. This 
could be explained by the commonly observed genetic divergence of metastasis 
from its primary tumor. In this case the time-span is 18 years between the primary 
tumor and the metastasis. Overall, the discordance rate is only 0.20% (1 assay 
out of 503 where both histological and cytological results are determined).
Tumor cell percentage and DNA quality
From biopsies and cytology, only small tumor foci can be microdissected. This 
results in a low DNA yield that, in case of formalin fixation, is also partially 
degraded. To study the quality of the DNA, we compared the DNA yield to assay 
performance. We observed that the average amount of DNA isolated (295 ng) was 
lower in the group (n=15) where two or more assays failed [as compared to the 
group without failing assays (n=102, 2973 ng)]. Nevertheless, in the latter group, 
44% of the samples (n=45) also had a DNA amount of lower than 295 ng. This 
indicates that Cq values are a better indicator of DNA quality and performance 
than DNA concentration measurements. 
Allele-specific qPCR with hydrolysis probes has been reported to surpass the 1% 
sensitivity level [27]. However, considering that the qPCR efficiency also depends 
on DNA fragmentation, the DNA isolated from FFPE samples could accurately be 
analyzed at a sensitivity level of 10% [26]. We determined the detection limit in 
serial dilutions of DNA from two tumors carrying a KRAS c.34G>T or a c.35G>A 
mutation. This showed that the minimal DNA input must be at least 32 pg, the 
equivalent of 4–6 cells of high molecular DNA, to give Cq values <35 (Figure 3). 
Furthermore, we validated the assays in a series of DNA isolates from 
microdissected FFPE samples with known KRAS, PIK3CA, BRAF or EFGR 
variants as determined by Sanger sequencing. We found a 100% correlation with 
the hydrolysis probe assays. 
We validated the assay for EGFR exon 19 in a series of 10 samples with possible 
sequence verified exon 19 deletions and a tumor percentage of more than 50%. 
The samples were tested without prior knowledge of the mutation status. The 
hydrolysis assay results were compared with the DNA sequence results and 
all nine samples containing an exon 19 deletion were correctly identified and 
distinguished from the wild-type specimen (Figure 2b). In one case, there was 
an 18-bp insertion in exon 19. Because this fell outside the detection area of 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































in Supplementary Table S3). These results show that all hotspot mutations and 
EGFR exon 19 deletions can be detected using the hydrolysis probes. 
Cross-reactivity
Mutations in KRAS and PIK3CA cluster in hotspots. For KRAS, all seven assays 
hybridized to codons 12 and 13 (nucleotides c.34G, c.35G and c.38G), while for 
PIK3CA two assays detected exon 9 changes (c.1624G>A and c.1633G>A). As 
the probes potentially hybridized in the same region, cross-reactivity between the 
different KRAS or PIK3CA assays might be observed as a result of increased 
fluorescence readings from imperfectly matched probes or primers [26]. 
Additionally, cross-reactivity might result from (rare) base pair substitutions that 
are not covered by the used assays. 
Cross-reactivity was studied in a series of 42 MD samples carrying a KRAS 
mutation at position 34, 35 or 38. A total of 294 assays (42x7) were performed. 
The correct mutation status was identified when an Rm/Rwt ratio cut-off >0.7 was 
used; however, in 68 assays, a cross-reactivity signal was observed. Five cross-
reactivity signals had Rm/Rwt>0.7, but in these cases, the assay for the genuine 
mutation had Rm/Rwt>1.0. Cross-reactivity was only observed for probes covering 
the same base pair position (at position 34 or 35). Cross-reactivity between signals 
from base pair 34 or 35 and position 38 was not observed (Supplementary Table 
S4). Therefore, it is probable that no cross-reactivity effects were observed for the 
two different PIK3CA probes. 
Clinical practice
The described methods can be implemented in clinical practice. The molecular 
diagnostics test results can be generated in a short time. In daily practice, the 
cytological EBUS-TBNA or EUS-FNA aspiration material is morphologically typed 
by pathologists. Subsequently, samples are clustered for microdissection on a 
weekly basis. Microdissection is essential to obtain high tumor cell percentages 
to detect the EGFR exon 19 deletion, and to allow other analyses with lower 
sensitivity than the described method, e.g Sanger sequencing. After DNA 
isolation, the hydrolysis probe assays are performed on the DNA dilutions. At the 
end of the second day, the qPCR results are analyzed in an in-house–developed 
Microsoft Excel–based analysis tool to interpret the results, e.g., determine the 
mutation status of each probe and interpret the effect of cross-reactivity. The 
results are subsequently reported to the clinic. A limitation of hotspot analysis is, by 
definition, that only the hotspot mutations are detected, while Sanger sequencing 
can identify all mutations in the PCR amplicon. In some cases, in which the 
mutation analysis does not meet the quality settings, Sanger sequencing will 
be performed. For Sanger sequencing, extra PCR reactions, reaction product 
purifications and electrophoresis must be performed, which will require two extra 
days in the analysis pipeline. 
NSCLC Mutation Analysis after Fine Needle Cytology
121 
Conclusion
We conclude that somatic mutation hotspot analysis for KRAS, PIK3CA, BRAF 
and EGFR of fine needle aspirations of mediastinal lymph nodes in NSCLC 
patients is accurate and reliable. Somatic hotspot mutation analysis for KRAS, 
PIK3CA, BRAF and EGFR can reliably be performed using allele-specific qPCR 
with hydrolysis probes; the mutation results from cytological specimens and the 
primary tumors are highly concordant.
Somatic mutation analysis in NSCLC for molecular staging and the guidance of 
treatment decisions can be performed on EBUS and EUS fine needle aspirates, 
procedures that are less invasive for the patient than routine mediastinoscopy. 
Our findings indicate that the molecular genetic analysis of NSCLC should be 
incorporated with the standard EBUS and EUS procedures. This combined 
approach will result in the accurate diagnosing and staging of those patients and 
will also help to guide the optimal treatment decisions, especially in stage III and 
IV NSCLC. 
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As a result of revolutionary technological advances, the molecular analysis 
of cancer field is growing rapidly. Mutations in KRAS, BRAF and EGFR have 
been discovered, and these biomarkers appear to be pivotal in critical cancer 
pathways. This knowledge led to the discovery of specific inhibitors that have 
been implemented in personalized medicine, for example in colorectal cancer and 
non-small-cell lung carcinoma [1]. Cancer genomes from tumor subtypes have 
been sequenced, revealing a landscape of somatic mutations. Potential critical 
mutations have been identified which may be favorable prognostic markers [2]. 
Epigenetic and transcriptional profiling of tumors contributed to the development 
of validated molecular classification tests such as Oncotype DX and MammaPrint 
for breast cancer. Therefore, the expectation is high that technological advances 
and an understanding of the molecular basis of cancer will translate to benefits 
for cancer patients [3]. 
What will technological advances in the next 5, 10 or 25 years bring to pathology? 
In his book De Toekomst van Gezondheid (The future of health), futurologist and 
trendwatcher Adjiedj Bakas predicts that in 2025 90% of oncology patients will 
be cured. Kurzweil, an American futurist and the current director of engineering 
at Google, believes that people living in 2050 could be close to immortal as a 
result of the combination of biotechnology and nanotechnology. In his bookThe 
Singularity is Near: When Humans Transcend Biology he predicts that cell repair 
nanobots will flow through the bloodstream in an era when artificial intelligence 
has become reality. These predictions are tempting and promising although only 
future will tell if they become reality or remain science fiction. Still, the question 
can be prompted whether a general direction in pathology can be distinguished 
by current advances and directions in technology. From a clinical point of view, 
future decision making strategies in pathology will continue to depend on 
histopathological features, and tumor typing, grading and staging will remain 
critical [4]. 
Major advances will be made with the expected implementation of digital pathology 
within the next decade. As a successor to standard microscopy digital pathology 
will imply that ultra-high-resolution (fluorescent) scanners for microscopic imaging 
will become available, and that pathologists will perform diagnostics using high-
resolution monitors with “Google Earth”-like zooming technology [5]. This field is 
expected to progress based on the development and application of specialized 
software for image analysis: “Apps” for digital pathology. These include algorithms 
for computer-assisted recognition of cells in which a plethora of cellular data (DNA, 
RNA, and protein) will be automatically assimilated in a form beyond the current 
scope of pathological diagnosis and the compass of the human eye [6]. In digital 
pathology genomic information can be accessed through the various techniques 
described in this thesis, while proteomic information may be accessed through 
new developments in spectral flow cytometry, Matrix-assisted laser desorption 
ionization (MALDI) imaging mass spectrometry (IMS), or a combination of mass 
spectrometry and flow cytometry [7–9]
Currently, metastatic cancer remains incurable and resistance or unresponsiveness 
to targeted therapies often develop. Therefore genetic screening should be 
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performed to identify new combined targeted agents and further efforts must be 
made to develop better anti-metastatic cancer drugs [10,11]. To identify patients 
who will benefit from novel, personalized therapies, more specialized methods 
must be continuously developed and adapted to routine diagnostic pathology 
[12]. Developments in research and progress in clinical practice make it essential 
to intensify collaborations between pathologists and clinicians as well as between 
molecular biologists, bio-informaticians and intermediaries. Database managers 
will be needed to organize and facilitate the dissemination of the massive amount 
of complex data. 
Currently, the application of high-throughput sequencing in FFPE material to 
molecular tumor diagnostics and research is not yet widespread. Methods and 
approaches have been developed that should be applied and evaluated on DNA 
isolated from FFPE samples. The routine sequencing of whole-cancer genomes 
will be the ultimate goal in high-throughput sequencing [13,14]. In the meantime, 
many labs will study the exons of all protein-coding genes in the genome. 
Alternatively, whole transcriptomes [15] or the epigenome [16] will be analyzed. 
High-throughput sequencing in molecular tumor diagnostics will most likely begin 
with the rapid sequencing of smaller subsets of genes on multiple samples with 
sufficient sequence depth to identify rare somatic variants in heterogeneous 
tumors [17–19]. This demand can be fulfilled by making use of smaller, faster, 
bench-top sequencers, such as the Illumina MiseqTM and Life Technologies Ion 
PGMTM and Ion ProtonTM sequencers, in combination with the targeted sequencing 
of “DNA barcoded” samples [20]. 
The currently available high throughput or next generation sequencing (HT-NGS) 
equipment is based on PCR, which may introduce artifacts that will be detected 
by this sensitive method. Therefore, methods that are suitable for sequencing 
DNA from a single molecule will eliminate the need for PCR and will be the next 
step in implementing “third-generation” sequencing in the laboratory. One of the 
first applications of single-cell sequencing was the Heliscope™ single molecule 
sequencer [21], and other approaches for single-cell sequencing, such as 
Single molecule real-time (SMRT™, Pacific Biosciences®) sequencing and RNA 
polymerase (RNAP) sequencing, have been developed [2,22]. 
Single-molecule nanopore sequencing does not require fluorescent labeling, 
which could further simplify sample preparation protocols, increase sequencing 
speed and reduce costs [23]. This method is patented by Oxford Nanopore 
Technologies® and is applied in the GridION and MinION sequencing systems. 
The MinION system is a miniaturized, portable device that is the size of a large 
USB flash drive and may bring next-generation sequencing to the operating 
room, bedside, or remote areas with few resources (http://www.nanoporetech.
com/ accessed September 2012). 
The implementation of this third-generation sequencing technology in molecular 
tumor diagnostics seems to be a matter of time and investment. It remains to 
be observed if next- or third-generation whole genome sequencing in clinical 
diagnostics will be cost effective, particularly if additional costs for analysis and 
data storage are taken into consideration [19]. Sanger sequencing has become 
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one of the first commercially exploited molecular technologies, and HT-NGS will 
likely become daily practice in sequencing efforts. In the near future, the basic 
steps in sample and library preparation will be performed in research and clinical 
laboratories, while the actual sequencing will be outsourced to commercial 
companies. 
Other issues in the progression toward implementing whole genome sequencing 
in clinics concern ethical considerations. How will doctors be educated about 
these testing methods and the interpretation of results? How will we manage novel 
variants of uncertain significance? How will we address incidental findings? How 
will concerns regarding privacy, potential abuse and discrimination be tackled 
[18,24]? These are serious considerations, particularly during a time period when 
it is possible and affordable for individual persons to have their “own” genome 
sequenced by commercial companies without any a priori clinical questions. In 
summary, a challenging future lies ahead; 70 years after Prof. Lignac’s seminal 
publication, his question can be repeated: “Quo Vadis?”.
As a consequence of the major technological advances in molecular pathology, 
SNP arrays and MLPA have been developed for the simultaneous analysis of 
many genetic loci in a relatively limited number of specimens. Applications of 
hydrolysis probe assays, PCR with M13-tailed primers, HRM as a mutation 
prescreening method and Sanger sequencing have contributed to the 
implementation of a largely automated workflow to detect mutations in extended 
series of samples. The implementation of next-generation sequence technology 
in molecular pathology is at hand. However, the application of these technologies 
using degraded DNA isolated from tiny amounts of formalin-fixed and paraffin-
embedded material remains a challenge. Specialized analytical tools have been 
developed by commercial companies. However, these software packages are 
not always appropriate for the analysis of tumors in which imbalances between 
wild-type and mutant alleles are often observed. Databases and laboratory 
information management systems (LIMSs) must be implemented and maintained 
in the analysis workflow. Original, “raw” and analyzed data should be archived 
and accessible at all times for data mining, review and future reference. 
Therefore, the development of dedicated software, analysis approaches and a 
reliable and secure data storage facility is critical to continuously keep pace with 
the newest developments and specific demands. In the near future, electronic 
pathological archives with microscopic images together with whole genome and 
whole transcriptome sequence data will become as important as the FFPE tissue 
archives have proven to be over the previous decades. 
Finally, molecular outcomes are not as black and white as the pharmaceutical 
industry would like. Factors such as minimal input, allelic imbalance, tumor 
heterogeneity and the role of the stroma must be considered and may present 
major challenges to mutation detection. Small subpopulations of cells, individual 
circulating tumor cells or tumor DNA may direct future therapeutic decisions 
and biomarker development, and the stroma is a key element of the tumor 
microenvironment [25,26]. Consequently, genomic analyses on individual tumor 
and stromal cells should be performed with an understanding of the risk of 
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contamination. DNA contamination must be considered because minimal amounts 
of patient material are available and the sensitivity of the utilized methods is 
increasing. Standard hydrolysis probe assays detect a mutation content of 1%, 
and if the wildtype allele is inhibited, a content of 0.1% or less can be identified. 
High-throughput sequencers can detect one mismatched DNA copy in 1000 or 
10,000 reads, depending on the methodology. Digital PCR, which has become 
the method of choice for detecting circulating tumor DNA or cells, has a detection 
limit of 1:100,000 [27]. In addition to the challenging question of how patients with 
a low copy mutant allele will respond to therapeutics, we must realize that DNA, 
contaminating or not, is present everywhere, and these are challenges for future 
molecular testing that will require high standards at the test facilities. 
These constantly evolving biological and technological insights make it necessary 
to concentrate molecular analysis in specialized laboratories. Only technologies 
that are general and widely used and validated can be applied in non-specialized 
routine laboratories. For instance, at the end of the 19th century H&E staining 
was first described and a specialized technique that could only be performed 
in specialized laboratories, but over time, virtually every hospital implemented 
this technique. In the same way, for some molecular testing methods, it is only a 
matter of time before tests become available for use in every hospital. However, 
keeping pace with new biological insights and technological developments and 
the implementation and maintenance of laboratories for molecular pathology in 
each hospital will likely be impossible and a waste of resources. More seriously, 
striving to keep pace with all technological advancements may even contribute to 
unnoticed false-positive and false-negative diagnoses. Therefore, a more rational 
direction for molecular tumor diagnostics must be taken, and initiatives for a few 
specialized centers that can be utilized by many hospitals must be exploited 
further. These well-equipped centers should have specialized employees to 
perform the tests and should continuously implement and develop new methods. 
These combined efforts will contribute to future advances in molecular pathology 
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This thesis describes technical advances in molecular tumor pathology that are 
related to the improved use of archives of formalin-fixed and paraffin-embedded 
tissue for molecular tumor diagnostics and research. The importance of isolating 
sufficient amounts of quality DNA from small fractions of FFPE material was 
confirmed, and we present examples of laboratory methodologies and analytical 
tools that have a large impact on cancer diagnosis, prognosis and therapeutics. 
In chapter 1, important developments in pathology are described in a general 
and locally applied historical perspective. An overview of different pathological 
consultations is presented with a short introduction of the most commonly 
used molecular technologies in research and diagnostics. Analysis strategies, 
beginning with the arrival of the tissue in the laboratory to the reporting of the test 
results, are discussed using a DNA analysis workflow. 
In chapter 2, we show that due to early diagnosis and adjuvant therapies, 
molecular tumor diagnostics has focused on the use of very limited pre-operative 
material. This makes high-quality DNA isolation challenging, particularly if the 
number of patients and the number of consultations per sample are increasing. A 
molecular analysis can only be performed if DNA of sufficient quality and quantity 
can be extracted from the archived tissue specimen. Therefore, we tested a fully 
automated DNA isolation system and compare it to our classical DNA isolation 
method. We determined that the fully automated method delivers high-quality 
DNA from small tissue cores and micro-dissected tissue. When the DNA is used 
in hydrolysis probe assays, we achieve a 24-hour faster turnover time, with 80% 
less hands-on time.
Multiplex ligation-dependent probe amplification (MLPA) is introduced in chapter 
3. MLPA can be used to detect multiple chromosomal aberrations in a single 
experiment. We developed an MLPA-based assay to determine losses in FFPE 
tissue from oligodendroglial tumors (OG) and validated the MLPA results by 
comparing them with fluorescence in situ hybridization (FISH). The MLPA results 
were reproducible in all samples for which repeated experiments were performed, 
and we conclude that MLPA is a valid and reproducible method for the detection 
of 1p/19q chromosomal deletions in OGs.
For a reliable workflow in MLPA, tools are needed for administrative support, 
data management, normalization, visualization, reporting and interpretation. In 
chapter 4, we describe a MLPA data management system that was developed 
in-house in which a statistical approach is applied for the normalization and 
analysis of a large series of MLPA traces, making use of multiple control samples 
and internal controls. This integrated approach aids in the automated handling 
of a large series of MLPA data and guarantees a quick and streamlined dataflow 
from the beginning of the experiment to the authorized report.
Summary
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The accurate detection of KRAS mutations is critical for the molecular diagnosis 
of cancer and may guide proper treatment selection. In chapter 5, we introduce 
a protocol for screening somatic mutations in KRAS that combines a whole-
genome amplification (WGA) and a high-resolution melting analysis (HRM) as a 
prescreening method for samples harboring mutations. Direct Sanger sequencing 
is subsequently applied to define the specific KRAS mutations in the samples. 
We illustrate that this method is feasible for the screening of clinical specimens by 
analyzing pancreatic cancers and that it can be applied to virtually any potentially 
mutated region in the genome.
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-
TBNA) and trans-esophageal ultrasound scanning with fine needle aspiration 
(EUS-FNA) are important techniques for the diagnosis and staging of NSCLC. 
In chapter 6, we demonstrate that allele-specific quantitative real-time PCR 
with hydrolysis probes can be accurately applied to EBUS and EUS fine needle 
cytological aspirates from NSCLC patients and that the mutations detected in 
the histological material of primary tumors can also be identified in cytological 
samples from the same patient. 
Chapter 7 presents concluding remarks and provides future directions in 
molecular pathology. Major improvements in molecular technologies have 
been achieved in recent decades. The clinical value of different tests has been 
proven. Next-generation sequencing and digital pathology are challenging new 
technologies that will be implemented in due time in the clinic to achieve better 





In de weefsel archieven van de afdeling Pathologie bevinden zich grote 
aantallen “blokjes” met formaline gefixeerd en in paraffine ingebed (FFPE) 
weefsel. Dit proefschrift beschrijft recente technologische vooruitgang in de 
moleculaire tumorpathologie waardoor de toegankelijkheid van deze archieven 
sterk is verbetert en de mogelijkheden voor moleculaire tumor diagnostiek en 
wetenschappelijk onderzoek sterk zijn toegenomen. Aangetoond wordt hoe 
belangrijk het is voldoende kwalitatief goed DNA van kleine fracties FFPE materiaal 
te isoleren. Voorbeelden worden gegeven van laboratorium-methoden en analyse 
tools die bijdragen aan verbeterde diagnose, prognose en therapie van kanker. 
In hoofdstuk 1 worden belangrijke ontwikkelingen in de pathologie vanuit een 
algemeen en lokaal toegepast historisch perspectief beschreven. Een overzicht 
wordt gepresenteerd van verschillende pathologische onderzoeksvragen en 
er wordt een korte introductie gegeven van de meest gebruikte moleculaire 
technieken in onderzoek en diagnostiek. Analyse-strategieën, te beginnen met 
de binnenkomst van het weefsel in het laboratorium, tot aan de rapportage van 
de testresultaten, worden besproken aan de hand van een schematische DNA-
analyse workflow. 
In hoofdstuk 2 laten we zien dat als gevolg van vroege diagnose en adjuvante 
therapieën, moleculaire tumor diagnostiek zich heeft ontwikkeld in de richting 
van analyses op uiterst kleine hoeveelheden pre-operatief materiaal. Dit maakt 
het isoleren van DNA van voldoende kwaliteit een uitdaging, vooral als zowel het 
aantal patiënten als het aantal consulten dat op het materiaal wordt aangevraagd 
toeneemt. Een moleculaire analyse kan alleen worden uitgevoerd als DNA 
van voldoende kwaliteit en kwantiteit wordt geïsoleerd uit het gearchiveerde 
FFPE weefsel. Daarom is een volledig geautomatiseerd DNA-isolatie systeem 
uitgetest en vergeleken met de klassieke DNA-isolatie methode. We stellen 
vast dat de volledig automatische methode DNA van hoge kwaliteit oplevert 
als het word geïsoleerd uit kleine hoeveelheden materiaal uit FFPE blokjes of 
gemicrodissecteerd materiaal van weefsel coupes. Als het DNA vervolgens wordt 
gebruikt in de zogenaamde hydrolyse probe assays wordt de doorloop tijd met 24 
uur verkort terwijl de “hands-on” tijd 80% minder wordt.
Multiplex ligatie-afhankelijke probe amplificatie (MLPA) wordt geïntroduceerd 
in hoofdstuk 3. MLPA kan worden gebruikt om een relatief groot aantal 
chromosomale afwijkingen tegelijkertijd te onderzoeken in een enkel experiment. 
Een MLPA test is ontwikkeld om verlies van heterozygositeit in FFPE materiaal 
van oligodendrogliale tumoren (OGT) te bepalen. De MLPA resultaten zijn 
gevalideerd door ze te vergelijken met “fluorescentie in situ hybridisatie” (FISH) 
experimenten. De resultaten zijn reproduceerbaar en we concluderen dat MLPA 




Voor een goede MLPA-workflow is een geautomatiserd data-analyse systeem 
van groot belang. In hoofdstuk 4 beschrijven we een zelfontwikkeld MLPA data 
management systeem waarin een statistische benadering wordt toegepast voor 
de normalisatie en de analyse van MLPA patronen. Deze geïntegreerde aanpak 
helpt bij de administratieve ondersteuning, normalisatie, visualisatie, rapportage 
en interpretatie van grote series MLPA gegevens. 
De nauwkeurige detectie van mutaties in het KRAS gen is van groot belang voor 
de moleculaire diagnose van verschillende typen kanker en kan helpen bij de 
keuze van de behandelingstrategie van de patiënt. In hoofdstuk 5 introduceren 
we een protocol voor het screenen van somatische mutaties in KRAS. Hierin word 
aansluitend aan een volledige genoom-amplificatie (WGA) een hoge-resolutie 
smelt analyse (HRM) uitgevoerd, die dient als mutatie pre-screenings methode. 
Vervolgens wordt op de monsters met een afwijkend smeltpatroon de specifieke 
KRAS mutatie vastgesteld met behulp van sequentiebepaling volgens de Sanger 
methode. We concluderen dat deze methode geschikt is voor de screening van 
klinische monsters pancreaskanker en dat de methode potentieel kan worden 
toegepast op vrijwel elk mogelijk gemuteerd gebied in het genoom.
Endobronchiale echogeleide transbronchiale naald aspiratie (EBUS-TBNA) en 
trans-oesofageale echografie met fijne naald aspiratie (EUS-FNA) zijn belangrijke 
technieken voor de diagnose en stadiëring van niet-kleincellig longcarcinoom 
(NSCLC). In hoofdstuk 6 tonen we aan dat allel-specifieke kwantitatieve real-time 
PCR met hydrolyse probes betrouwbaar kan worden toegepast op vaak minimale 
hoeveelheden via EBUS-TBNA en EUS-FNA verkregen cytologisch materiaal 
van NSCLC patiënten, en dat de gedetecteerde mutaties overeenkomen met 
de mutaties in het histologische materiaal van primaire tumoren van dezelfde 
patiënt.
De toekomstige ontwikkelingen in de moleculaire pathologie en enkele 
concluderende overwegingen worden beschreven in Hoofdstuk 7. In de 
afgelopen decennia zijn belangrijke verbeteringen in moleculaire technologieën 
verwezenlijkt. De klinische waarde van verschillende moleculair pathologische 
testen is bewezen. “Next-generation”-sequentiebepaling en digitale pathologie 
zijn belangrijke nieuwe methodes die in de nabije toekomst in de kliniek zullen 
worden toegepast waarbij de huidige archieven met FFPE materiaal op een nog 
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